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To my beloved family
“Nature is nowhere accustomed more openly to display her secret mysteries 
than in cases where she shows traces of her workings apart from the beaten 
path; nor is there any better way to advance the proper practice of medicine 
than to give our minds to the discovery of the usual law of nature by the care-
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Background and aims: Mulibrey nanism (MUL; OMIM 253250) is an autosomal 
recessive disorder belonging to the Finnish disease heritage and currently clas-
sified as a peroxisomal disorder. MUL is characterized by intrauterine-onset 
growth restriction, typical dysmorphic features, restrictive perimyocardial heart 
disease, and severe insulin resistance. The causative gene, TRIM37, is located on 
chromosome 17q22-q23 and encodes for a peroxisomal protein (TRIM37) with 
ubiquitin E3-ligase activity, suggesting its role in proteasomal protein degrada-
tion. All 19 mutations identified to date, including 4 in Finnish patients, are 
likely to produce a non-functioning protein. 
For many decades, the clinical care and follow-up of Finnish MUL patients were 
based at the Children’s Hospital in Helsinki, generating a unique clinical experi-
ence and data set for this patient group. In follow-up, it became evident that a 
substantial proportion of these patients developed hypogonadism, were infer-
tile, and had an increased risk of developing tumors. Thus, the principal focus 
of this study was to characterize the hypogonadism and infertility associated 
with this disorder, and furthermore to define the tumors and tumor predisposi-
tion in MUL, both clinically and immunohistochemically.
Patients and methods: A total of 92 Finnish patients (0.7-77 years) were includ-
ed in the study; 22 post pubertal females participated in the female hypogo-
nadism study, and 28 male patients participated in the male hypogonadism 
study. All hospital records were evaluated, and physical, laboratory, and radio-
logical examinations were performed according to clinical protocols. Biopsies 
(taken on clinical grounds) and autopsy samples were used for histological and 
immunohistochemical studies. In addition, 15 freshly frozen samples from spo-
radic ovarian fibrothecomas were analyzed for the role of TRIM37 in the devel-
opment of these tumors. 
Results: All MUL patients developed hypogonadism due to a primary gonadal 
defect and were either infertile or severly subfertile. Women demonstrated 
spontaneous puberty, incomplete breast development, and early irregularity 
of menstrual periods with subsequent ovarian failure. Their ovaries were hy-
poplastic and their uteri were small. The men also experienced spontaneous 
puberty with somewhat small testes characterized by varying degrees of de-
generation and few mature germ cells. Semen samples showed either severe 
oligoasthenozoospermia or azoospermia. No spontaneous pregnancies had 
been conceived among the MUL patients. Four men had undergone infertil-
ity treatment, which in one case was successful, resulting in the delivery of a 
healthy child.
7ABSTRACT
The MUL patients displayed a high frequency of both benign and malignant 
tumors especially of endocrine origin. A total of 232 tumorous lesions in sever-
al different organs were discovered in the patient cohort. Histologically, the ar-
chitecture of several organs was disturbed, indicating aberrant organogenesis. 
One of the most frequent tumors was ovarian fibrothecomas, which are fairly 
uncommon in the general population, found in 55% of the female patients.
Conclusions: The study of inherited monogenic disorders has contributed sub-
stantially to our understanding of gene function and human disease. In MUL, 
mutations in TRIM37 lead to failure of sexual maturation in both females and 
males, and fertility is seriously compromised. In addition, the patients are at a 
very high risk for developing benign and malignant tumors in several different 
organs. This study suggests a role for TRIM37 protein in the cellular functions 
governing gametogenesis, gonadal function, and proliferation. 
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1. INTRODUCTION
A rare disease is classified as such when it affects a limited number of indi-
viduals (<1:2000 in Europe and <1:1250 in the USA) (Ong and Devuyst 2011). 
Therefore, by this definition, more than 5000 rare diseases exist (Schieppati 
et al. 2008), and the number of affected patients could number 30 million in 
Europe and 25 million in the USA (Ong and Devuyst 2011). Rare diseases are 
mostly genetic disorders, which are often chronic, disabling, and affecting life 
expectancy. Thus, they may be a severe burden for the affected patients and 
families. Lately, it has been increasingly recognized that rare diseases are an 
important medical and social issue (Schieppati et al. 2008). The study of in-
herited monogenic disorders has contributed greatly to our understanding of 
gene function and the pathophysiology of diseases, but there is also increasing 
evidence that monogenic defects play a significant, and previously underesti-
mated, role in complex disorders (Ropers 2010). 
The Finnish disease heritage comprises 36 rare monogenic diseases that are 
overrepresented in Finland (Norio 1973, 2003). These diseases have been the 
subject of intensive genetic and molecular research over the past 20 years, and 
to date, the genetic background of all the disorders has been characterized 
(Kestilä et al. 2010). These studies have often provided novel information on 
biological processes and metabolic pathways essential for normal cell function 
and development (Peltonen et al. 1999).
Mulibrey nanism (MUL; OMIM 253250) is a dysmorphic growth disorder be-
longing to the Finnish disease heritage and first described by Perheentupa and 
colleagues in the early 1970s (Perheentupa et al. 1970, 1973). The name is an 
acronym from muscle hypotonicity (MUscle), hepatomegaly (LIver), enlarged 
ventricles of the central nervous system (BRain), and yellowish dots of the ocu-
lar fundi (EYe). The term nanism, adapted from Latin, stands for short stature. 
For many decades, the clinical care and follow-up of MUL patients in Finland 
were based at the Children’s Hospital in Helsinki, generating a unique clinical 
experience and data set for this patient group, which constitute the founda-
tion of this study.
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2. REVIEW OF THE LITERATURE
2.1 The Hypothalamic-Pituitary-Gonadal Axis
The adequate function of the hypothalamic-pituitary-gonadal (HPG) axis is es-
sential for normal gonadal development, sex steroid production, and fertility. 
Defects at any level of the axis can lead to hypogonadism and subsequent 
impairment of fertility. The HPG axis is fully active during fetal life (Kaplan et 
al. 1976) and during the newborn period (Winter et al. 1975), but thereafter 
becomes relatively quiescent until puberty (Terasawa and Fernandez 2001).
Reactivation of the HPG axis, manifested by an increased synthesis and pulsa-
tile release of gonadotropin-releasing hormone (GnRH) from the hypothala-
mus, indicates the onset of puberty. GnRH stimulates the secretion of lutein-
izing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior 
pituitary gland, which in turn stimulate the ovaries and testes to produce the 
sex steroids estrogen and testosterone, respectively. FSH and LH are both pro-
duced by the same cells —  the gonadotropes — in the pituitary, in proportions 
that are at least in part defined by the GnRH pulse frequency (Krsmanovic et 
al. 2009).
The sex steroids, estrogen and testosterone, exert a negative feedback inhibi-
tion on both hypothalamic GnRH and pituitary gonadotropin release, together 
with inhibin B and follistatin (Figure 1). Inhibin B is a gonadal glycoprotein, 
which specifically regulates FSH secretion (Illingworth et al. 1996). The peptide 
follistatin is produced in many tissues and exerts its negative feedback effects 
by inhibiting activin, a stimulatory peptide. LH and FSH induce the final stages 
of gonadal development, leading to the production of mature gametes and 
sex steroids (Grumbach 2002). 
                     
Figure 1. The HPG axis. GnRH, gonadotropin-releasing hormone, LH, luteiniz-
ing hormone, FSH, follicle-stimulating hormone. Modified from Achermann and 
Jameson 1999.
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2.1.1 HPG Axis in Infancy and Childhood
Hypothalamic GnRH secretion begins by the end of the first trimester (Kaplan 
et al. 1976). At birth, FSH and LH levels are low because of an inhibitory effect 
of placental steroids, especially estrogen (Grumbach 2005). Within 2 weeks of 
age, when the placenta-derived steroids have dispersed, a reactivation of the 
HPG axis occurs. This “minipuberty” results in an increase of FSH and LH and 
subsequently gonadal sex steroid levels (Schmidt and Schwarz 2000). During 
this period, gonadotropin levels reach their maximum between 4 and 10 weeks. 
In males, LH levels predominate, whereas in females, FSH levels predominate. 
This period of postnatal pituitary activation is considered to be important for 
normal reproductive development in boys, since during this period, there is an 
increase in the number of Sertoli and germ cells, growth of the penis and tes-
tes, and augmented testicular testosterone secretion (Grumbach 2005, Lewis 
and Lee 2009, Kuiri-Hänninen et al. 2011a). The importance of the minipuberty 
for female reproductive development is not equally well understood (Kuiri-
Hänninen et al. 2011b). After the transient activation of the pituitary, gona-
dotropin levels gradually decline (Isidori et al. 2008). Already in childhood, the 
gonads secrete small amounts of estrogen and testosterone (Mitamura et al. 
1999, 2000), but only a sufficient increase in their plasma levels will induce 
the development of the secondary sex characteristics and the pubertal growth 
spurt. 
2.1.2 Puberty
Puberty is the transitional period from childhood to adulthood, during which 
the secondary sex characteristics appear, the growth spurt occurs, marked phys-
iological changes take place, and fertility is achieved. Both genetic and envi-
ronmental factors regulate the timing of puberty. The mechanisms that initiate 
puberty are not completely understood, but involve genes such as KISS1 (en-
coding for the neuropeptide family of kisspeptins), and a shift in the balance 
of inhibitory neurotransmitters, such as GABA (gamma-aminobutyric acid), and 
neurostimulators, such as glutamate (Plant 2008, Belchetz et al. 2010). The end 
point of the pubertal process is the ability to reproduce.
The development of the secondary sex characteristics is driven by both the 
increase in GnRH stimulated sex steroids and adrenal androgens. Adrenarche, 
which develops independently of HPG-axis maturation, occurs about two years 
before the onset of puberty. Approximately two years before the first physical 
signs of puberty, there is also an increase in the nocturnal pulsatile release of 
GnRH, leading to an increased secretion of LH at night. In addition to LH, girls 
also show an increased secretion of FSH (Manasco et al. 1997). The nocturnal 
LH pulses gradually increase, both in amplitude and frequency, as the onset of 
puberty advances, and finally also occur during the daytime. In males, testos-
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terone levels increase quickly and a circadian rhythm is established where the 
testosterone levels are markedly higher in the early morning than during the 
rest of the day. In girls, there is not an equally clear circadian rhythm in estra-
diol levels, but they tend to peak during the morning as well, and increase with 
Tanner stage (Norjavaara et al. 1996). 
Generally, pubertal development proceeds in a specific order, described by 
Tanner stages 1 through 5 for breast, genital and pubic hair growth (Marshall 
and Tanner 1969, 1970). In girls, the appearance of breast tissue (Tanner breast 
stage 2, B2) is usually the first sign of puberty (Marshall and Tanner 1969). In 
boys, the first sign is usually the enlargement of the testes to a volume of 3 
ml or more (Tanner genital stage 2, G2) (Marshall and Tanner 1970, Biro et al. 
1995). The mean age for achieving B2 and G2 in Finnish children is 10.8 and 
12.2 years, respectively (Ojajärvi 1982). Menarche, i.e. the first menstrual bleed-
ing, is quite a late occurrence in female puberty, manifesting approximately 2.3 
years after reaching B2. It may, however, sometimes be the first sign of puberty 
(Marshall and Tanner 1969, Tanner and Whitehouse 1976). Mean age at menar-
che for Finnish girls is 12.9 years (Niinikoski et al. 2007). 
Normal growth can be divided into intrauterine, infant, childhood, and puber-
tal growth, finally resulting in adult height (Karlberg et al. 1987a,b, Karlberg 
1989, Clayton and Gill 2001). Pubertal growth is characterized by an increased 
tempo (the pubertal growth spurt), which usually in boys occurs at Tanner G3. 
The gradually increasing secretion of the gonadal sex steroids mostly drives 
the pubertal growth spurt. In addition, rising growth hormone (GH) levels also 
contribute. In fact, GH is compulsory for optimal gonadal growth and develop-
ment of secondary sex characteristics (Bordini and Rosenfield 2011). In selective 
GH resistance (Laron syndrome), patients possess small testes and a micropenis, 
poor breast and sexual hair development, and lack of pubertal growth spurt 
(Laron 2002). In girls, the growth spurt is often the first sign of puberty, togeth-
er with B2 (Tanner and Whitehouse 1976). The highest velocity of the pubertal 
growth spurt is usually reached at Tanner stage 3 in girls, and stage 4 in boys. 
After this, growth velocity gradually decreases, during which time menarche 
usually occurs in girls (Tanner and Whitehouse 1976). 
2.2 Ovarian Health
Healthy ovarian function is essential for the general health of a woman and for 
the production of sex steroids, which are needed for the development of the 
genital tract and for bone density (De Vos et al. 2010). In the embryo, primor-
dial germ cells migrate from the yolk sac to the urogenital ridge, which in the 
female embryo becomes the ovary. The oogonia proliferate to ultimately form 
a total of 7 x 106 oocytes in the ovaries by about 20 weeks of gestation. After 
this, there is a continued loss of ovarian follicles through programmed cell 
death, apoptosis (Baker 1963, Hsueh et al. 1994, 1996, Vaskivuo et al. 2001). At 
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the time of birth, each ovary has a fixed number of primordial follicles, usually 
about 1 x 106. This number is constantly reduced throughout life because of 
atresia and recruitment to ovulation (Gosden and Faddy 1998) (Figure 2). The 
newborn infant has already lost over 80% of her original germ cell pool, and 
by puberty, the number has decreased to 300,000. Less than 500 of the original 
7 x 106 (0.007%) oocytes are ovulated during the entire reproductive life span 
of a woman (Anasti 1998).
           
Figure 2. Decline of the ovarian follicular reserve. Shaded area indicates level of 
follicle population at which ovarian failure or menopause occurs. p5=5th percentile, 
p50=median, p95=95th percentile. Modified from De Vos et al. 2010.
2.2.1 Normal HPG Axis during Adult Female Life
During adult female life, an active pulsatile GnRH stimulated secretion of FSH 
and LH is imperative for the maintenance of secondary sex characteristics and 
for sexual function (Krsmanovic et al. 2009) (Figure 3). The development of 
a cyclic, regular ovulatory menstrual cycle results from stringently controlled 
interactions between the hypothalamus, pituitary, ovaries, and genital tract. 
The normal menstrual cycle can be divided into two main phases: the follicular 
(proliferative) phase and the luteal (secretory) phase. The follicular phase be-
gins on the first day of the cycle, which is also the first day of menstruation. This 
phase is characterized by the growth and maturation of the dominant follicle 
and by proliferation of the uterine endometrium. Low basal levels of LH stimu-
late the theca cells to produce androgens. While theca cells lack aromatase, 
which is needed for conversion of androgens to estrogens, the androgens are 
transported to the adjacent granulosa cells, where FSH stimulates their con-
version to estrogens. The primordial follicles are composed of an oocyte sur-
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rounded by a single layer of granulosa cells. Under the stimulation of FSH, the 
primordial follicles will grow into the preovulatory follicle stage, where many 
layers of granulosa cells and an outer layer of theca cells surround the oocytes. 
During the midfollicular stage, usually one dominant follicle will continue to 
grow while the other follicles that have been developing undergo atresia and 
degenerate (Hawkins and Matzuk 2008).
                            
Figure 3. HPG axis in females. Adapted from Bellin et al. 2009.
FSH also stimulates the synthesis of inhibin B and activin by the follicles. Inhibin 
B provides negative feedback to selectively inhibit FSH synthesis and release, 
whereas activin amplifies LH action on theca cells. The resulting increasing in-
hibin B and estradiol levels consequently inhibit the secretion of FSH at the pi-
tuitary level. The rising levels of estradiol during the late follicular phase stimu-
late the release of LH. This surge in LH induces ovulation and the subsequent 
formation of the corpus luteum, which is formed from the theca and granulosa 
cells that remain from the dominant follicle after the release of the oocyte.
Ovulation indicates the beginning of the luteal phase, where the corpus lu-
teum synthesizes progesterone and estrogen for two weeks to prepare the 
uterine endometrium for implantation of the fertilized egg. In case there is 
no implantation, the corpus luteum regresses, estrogen and progesterone lev-
els fall, the endometrium will be discarded as menstrual bleeding, and a new 
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menstrual cycle will begin. The median length of a normal menstrual cycle is 28 
days (range 25-30 days) (Treloar et al. 1967, Vollman 1977).
2.2.2 Premature Ovarian Failure 
Many factors can lead to disturbed ovarian function, such as hypothalamic-pi-
tuitary disorders, adrenal dysfunction, or polycystic ovary syndrome; however, 
premature or primary ovarian failure implies that the primary defect lies in the 
ovary. Through the years, different terms have been used to describe devia-
tions in healthy ovarian function, for example premature menopause, prema-
ture ovarian failure, and primary ovarian insufficiency. Recently, some authors 
have suggested that premature ovarian insufficiency (POI) would be a more 
accurate term than premature ovarian failure, since ovarian insufficiency can 
be used to describe a wider range of impaired ovarian function and POF can 
have a long and variable clinical course (Welt 2008, Nelson 2009, De Vos et al. 
2010). However, no international consensus has thus far been reached (Shelling 
2010), and in the literature, both terms continue to be used in parallel.
POF affects 1-2% of women under the age of 40 years and 0.1% of women 
younger than 30 years of age (Coulam et al. 1986), and is a major cause of 
female infertility. In Western populations, the median age for menopause is 
approximately 51 years (Morabia and Costanza 1998). POF refers to the devel-
opment of amenorrhea due to depletion of ovarian follicles before the age of 
40 years. The condition is characterized by amenorrhea (for at least 4 months), 
elevated FSH-levels (detected on at least two occasions one month apart), and 
sex steroid deficiency (Welt 2008). Women with POF present with primary or 
secondary amenorrhea, infertility, elevated gonadotropins, and low estrogen 
levels. 
2.2.3 Pathophysiology of POF
Perception of the causes for POF requires an understanding of the highly or-
ganized and complex process of ovarian follicular maturation, folliculogenesis 
(Figure 4). Folliculogenesis implicates the continuous maturation of small pri-
mordial follicles to large ovulatory follicles. The follicle consists of the oocyte 
surrounded by supporting somatic cells (granulosa and thecal cells), which are 
essential for the growth and development of the follicle. The final outcome of 
folliculogenesis is either ovulation or follicular atresia. Usually, only one oocyte 
is released from the surface of the ovary in ovulation. The granulosa and thecal 
cells, which are regulated by the gonadotropins FSH and LH, synthesize and se-
crete hormones and growth factors. Many of the molecules that are important 
for the regulation of follicular maturation are also known to be defective in 
some cases of POF.
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Figure 4. The process of folliculogenesis. Modified from Matzuk et al. 2002, Murphy 
2010, Persani et al. 2010.
Generally, POF arises either from depletion or dysfunction of ovarian follicles 
(Rebar and Connolly 1990). Depletion of ovarian follicles can result from either 
a decreased number of oocytes formed during embryonic development or an 
increased rate of oocyte atresia during reproductive life. Follicular atresia oc-
curs by means of programmed cell death, apoptosis. Thus, alteration in the rate 
of apoptosis may result in early ovarian failure. Follicle dysfunction, which is 
more uncommon, implies that follicles remain in the ovary, but a pathologic 
process prevents their normal function (Nelson 2009). To date, the causes of 
POF are substantially unknown (Woad et al. 2006).  Identified causes include 
iatrogenic agents, such as chemotherapy or radiation therapy, autoimmune 
conditions, X-chromosome abnormalities, and autosomal genetic conditions. 
POF has a strong genetic component, but most causes of POF remain unknown 
and the genes that have been found explain only a modest portion of POF 
cases (Persani et al. 2010, Shelling 2010) (Figure 5). 
                 
Figure 5. Causes of POF. Adapted from Shelling 2010.
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2.2.4 Genetic Causes of POF and Female Infertility
Given that part of the phenotype of POF is infertility, it is understandable that 
reproductive disorders like POF do not have large family histories (Shelling 
2010). Thus, they are difficult to study using traditional genetic methods such 
as linkage analysis. The genetic background of POF can be divided to syndromic 
forms (when the defect is a part of a complex phenotype involving other or-
gans and tissues), and to non-syndromic forms (when ovarian failure develops 
apparently isolated in a woman before 40 years of age) (Persani et al. 2010).
2.2.4.1 Syndromic POF
X chromosome abnormalities, both structural and numerical, account for a signifi-
cant number of the genetic causes of POF (Goswami and Conway 2005). Turner 
syndrome (TS) is the most common congenital cause of POF. TS occurs in approxi-
mately 1 in 2500 live female births, and is characterized by short stature, ovarian 
dysgenesis and neurocognitive problems. More than 50% of TS patients have the 
45,X karyotype, whereas others demonstrate 46,XX with the paired X chromo-
some carrying some type of abnormality (Sybert and McCauley 2004). The ovaries 
of a 45,X fetus appear completely normal until 14-18 weeks gestation, after which 
there is loss of oocytes and fibrosis of the ovarian stroma (Weiss 1971, Singh and 
Carr 1966). As a result, the majority of TS girls have complete, or near-complete, 
follicular atresia already prenatally or during the first months or years of postnatal 
life. Up to 30% of TS girls may, however, experience some pubertal development 
and spontaneous pregnancies have been reported in 2-5% (Pasquino et al. 1997, 
Hovatta 1999, Hreinsson et al. 2002). Women with mosaic TS (45,X/46,XX) may 
have menarche and a normal menstruation for many years (Sybert and McCauley 
2004). Genetic imprinting, karyotype, and degree of mosaicism influence the vari-
ation in phenotype (Skuse et al. 1997, De Vos et al. 2010). 
APECED (autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy; 
OMIM 240300) is an autosomal recessive disease belonging to the Finnish disease 
heritage. Patients present with two out of three major clinical symptoms, includ-
ing Addison’s disease, hypoparathyroidism, and chronic mucocutaneous candidia-
sis. Frequently, patients also exhibit various other autoimmune manifestations, 
such as thyroiditis, diabetes mellitus, and ovarian failure (Perheentupa 1996, 2006, 
Peterson and Peltonen 2005). The autoimmune regulator (AIRE) gene has been 
identified as the locus underlying the susceptibility to APECED (Finnish-German 
APECED Consortium 1997, Nagamine et al. 1997). To date, more than 60 variants 
of this gene have been found, and recent studies have also identified influences 
by other genetic loci, for example the human leukocyte antigen (HLA) complex 
(Mathis and Benoist 2007). In a Finnish study of 72 patients, hypogonadism was 
present in 60% of female patients over the age of 12 years (Perheentupa 1996). 
Male patients may also present with hypogonadism, but not as frequently as fe-
males (Perheentupa 2006).
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Ovarian failure also results from mutations in FOXL2 (forkhead box L2), lead-
ing to blepharophimosis-ptosis-epicanthus-inversus syndrome (BPES; OMIM 
110100). BPES is an autosomal dominant condition characterized by complex 
eyelid malformation. Two forms of the disorder have been recognized: type I, 
in which affected females have POF, and type II, which is not connected with 
POF (Zlotogora et al. 1983). The FOXL2 gene on chromosome 3q22-q23, en-
coding for a winged helix/forkhead transcription factor, is mutated in both 
BPES I and II (Crisponi et al. 2001). FOXL2 plays an important role in ovarian 
differentiation and maintenance (Cocquet et al. 2002) and was the first hu-
man autosomal gene in which dominant mutations were implicated in ovarian 
dysfunction. FOXL2 is mainly expressed by undifferentiated granulosa cells in 
the ovary (Pisarska et al. 2004).  In Foxl2 knockout mouse ovaries, a default 
granulosa cell differentiation leads to premature activation of primordial fol-
licles and subsequent follicular depletion and atresia (Schmidt et al. 2004). 
Although mutations in FOXL2 have been demonstrated in a few isolated cases 
of non-syndromic POF (Harris et al. 2002), other studies of phenotypically nor-
mal women with POF indicate that mutations in the FOXL2 coding region are 
seldom associated with non-syndromic POF (De Baere et al. 2001, 2002, Bodega 
et al. 2004). 
Ataxia telangiectasia (AT; OMIM 208900) is an autosomal recessive neurode-
generative disorder caused by mutations in the ATM (ataxia telangiectasia mu-
tated) gene encoding for a protein kinase that is involved in cell cycle regula-
tion and DNA repair (Shiloh 2003, Kastan and Bartek 2004). The disorder is 
characterized by uncoordinated movements, ocular telangiectasias, chromo-
some instability, radiosensitivity, immunodeficiency, and predisposition to can-
cer (Boder 1985, Savitsky et al. 1995, Lavin 2008). Female AT patients frequently 
present with ovarian failure and infertility due to gonadal hypoplasia with 
complete absence of mature oocytes (Miller and Chatten 1967, Persani et al. 
2010). Atm-deficient mutant female mice are also infertile and have extremely 
small ovaries with lack of primordial and mature follicles and oocytes (Barlow 
et al. 1996). Nontheless, no studies have been made into the potential role for 
the ATM gene in non-syndromic POF cohorts. 
Classic galactosemia (OMIM 230400) is a rare, autosomal recessive disorder 
of galactose metabolism, with an estimated incidence of 1:23000-1:44000 in 
Western Europe (Bosch 2006).  It is caused by deficiency of the GALT (galac-
tose 1-phosphate uridyltransferase) enzyme (Leslie et al. 1992), leading to the 
accumulation of galactose and its metabolites, which subsequently leads to 
abnormalities in glycosylation. Classic galactosemia causes a toxic neonatal syn-
drome that can be reversed with a lifelong galactose restricted diet; however, 
despite prompt dietary intervention, most patients already develop long-term 
complications at a young age, including delayed growth and speech, ataxia, 
tremor, and diminished bone mineral density (Waggoner et al. 1990, Bosch 
2006). Female patients with classic galactosemia commonly demonstrate de-
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layed pubertal development and amenorrhea, or oligomenorrhea. It was previ-
ously estimated that 60-70% of female patients develop POF, but follow-up of 
patients has revealed that the correct number is close to 100% (Kaufman et al. 
1981, 1986, Waggoner et al. 1990, Gubbels et al. 2008). Nontheless, pregnan-
cies have been reported (Gubbels et al. 2008, Rubio-Gozalbo et al. 2010). Thus 
far, there is no evidence for an association between mutations in GALT and 
idiopathic POF (Mlinar et al. 2005). Limited data are available on the gonadal 
status of male patients with galactosemia, but fertility does not seem to be 
impaired (Rubio-Gozalbo et al. 2010).
2.2.4.2 Non-Syndromic POF
Despite rigorous efforts, no single gene on the X chromosome has been con-
sistently found to be involved in the pathogenesis of POF to date. The fragile-X 
mental retardation 1 gene, FMR1, lies on Xq27 and is responsible for the de-
velopment of fragile X syndrome (Jacquemont et al. 2007). Interestingly, POF 
has been linked to the untranslated region of the FMR1 transcript (Sullivan et 
al. 2005). Expansion of a CGG repeat sequence in the 5’ untranslated region of 
FMR1 is associated with changes in the amount of FMR1 mRNA and protein, 
and leads to varying phenotypes (Jacquemont et al. 2007). Expansions of over 
200 repeats are considered to be a full mutation and they lead to the fragile 
X syndrome in males (Garber et al. 2006). Smaller expansions, between 55 and 
200 repeats, are known as pre-mutations, which are unstable and may expand 
to full mutations when transmitted maternally (Maddalena et al. 2001). Women 
with pre-mutations have a ten times higher risk of developing POF, while those 
with a full mutation or a normal range of repeats are not at an increased risk 
of POF (Conway et al. 1998, Allen et al. 2007, Persani et al. 2009). 
Bone morphogenetic protein 15 (BMP15) is a member of the TGFβ superfamily 
and is specifically expressed in the oocyte during early folliculogenesis. This 
growth and differentiation factor is critical for follicular development as it reg-
ulates many processes in the granulosa cells (Dube et al. 1998, Shimasaki et al. 
2004). The BMP15 gene is located at Xp11.22 (Dube et al. 1998). Mutations in 
BMP15 are associated with both primary and secondary amenorrhea in many 
worldwide POF cohorts with a prevalence of 1.5-12% (Persani et al. 2010). 
However, some studies have also failed to find an association between BMP15 
mutations and POF (Takebayashi et al. 2000, Chand et al. 2006). Thus the role 
of BMP15 mutations in the etiology of POF remains uncertain, but they could 
potentially function as susceptibility factors for this condition.
Mutations in many autosomal genes have also been associated with POF. It 
would be reasonable to consider that the hormones associated with the HPG 
axis would constitute good candidate genes for regulating oocyte atresia. 
Abnormalities in the key regulating hormones, such as FSH, LH, and their 
receptors, are not frequent causes of POF, however. A recessive mutation in 
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the FSH-receptor gene (FSHR), mapping to 2p21, has been linked to POF in a 
number of Finnish families (Aittomäki et al. 1995). Other populations, howev-
er, have not commonly reported this mutation (Shelling 2010). All females with 
the FSHR mutation are infertile. Similarly, female Fshr knockout mice (FORKO) 
are also infertile, which is due to a block in folliculogenesis at a primary stage. 
Interestingly, an intra-ovarian injection of adenovirus expressing human FSHR 
gene in these mice is able to restore the responsiveness to FSH, and to re-
establish ovarian folliculogenesis and continue the production of estrogen 
(Ghadami et al. 2010). Males homozygous for the FSHR mutation demonstrate 
varying degrees of spermatogenic failure but are not infertile by definition, 
indicating that normal FSH action is not as crucial for spermatogenesis as it is 
for ovarian follicle maturation (Tapanainen et al. 1997).
NR5A1 (nuclear receptor subfamily 5, group A, member 1), also known as SF1 
(steroidogenic factor 1), is an orphan nuclear receptor, which is essential for 
gonadal development and ovarian steroidogenesis (Luo et al. 1994, Lin and 
Achermann 2008). Recently, the NR5A1 gene, located at 11q13, has been 
shown to have a key role in ovarian development and function (Lourenço et 
al. 2009). The NR5A1 protein regulates the expression of central genes in the 
HPG axis that are involved in sexual development and reproduction, including 
STAR (encoding for steroidogenic acute regulatory protein), AMH (encoding 
for anti-Müllerian hormone) and INHA (encoding for inhibin alpha subunit). 
Newborn Nr5a1-/- mice lack both gonads and adrenal glands, and exhibit dimin-
ished expression of gonadotropins (Luo et al. 1994), thus supporting a key role 
for Nr5a1 in ovarian development and function in the mouse. Mutations of 
human NR5A1 have been known to cause 46,XY disorders of sex development 
(Achermann et al. 1999), and were recently shown to cause POF in otherwise 
healthy 46,XX females (Lourenço et al. 2009).
The FOXO3a (forkhead box O3A) gene belongs, like FOXL2, to the forkhead 
gene family and encodes for a transcriptional regulator. The gene maps to 
6Q21 and has a role in ovarian development and function (Watkins et al. 2006). 
Foxo3a knockout mice are sterile because of an accelerated activation of ovar-
ian follicles. Once activated, follicles have a limited lifespan, meaning that in 
Foxo3a knockout mice, premature follicle activation induces an early death of 
most oocytes (Castrillon et al. 2003). To date, the relevance of this mutation for 
the development of POF in humans is still unknown. Despite the fact that one 
study observed eight variations in FOXO3a in women with POF (Watkins et al. 
2006), the implications of these variations remain unclear (Cordts et al. 2011).
Growth differentiation factor 9 (GDF9) is a member of the TGFβ superfamily. 
The GDF9 gene is located on chromosome 5q23 and is highly homologous to 
BMP15. GDF9 is specifically expressed in the oocytes and acts in a synergistic 
manner with BMP15 on folliculogenesis and granulosa cells (Yan et al. 2001). 
Mutations in GDF9 have been found in non-syndromic POF patients (Otsuka et 
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al. 2011), but the results have not been consistent. Interestingly, Gdf9-/- mice are 
infertile (Dong et al. 1996), while Bmp15-/- mice are subfertile (Yan et al. 2001). 
The NOBOX (Newborn Ovary Homeobox) gene encodes for an oocyte-specific 
transcription factor important in the transition from primordial to primary fol-
licles (Rajkovic et al. 2001, Suzumori et al. 2002). While Nobox-/- mice are infer-
tile (Rajkovic et al. 2004), results in POF populations have been inconclusive; 
however, NOBOX mutations were recently found with a prevalence of 6.2% 
in one POF population (Bouilly et al. 2011), supporting a potential role for 
NOBOX mutations in the etiology of POF. Interestingly, GDF9 seems to be di-
rectly regulated by NOBOX.
The inhibins are heterodimeric glycoproteins that are primarily produced in 
the gonads (Tong et al. 2003). They are members of the TGFβ superfamily and 
consist of α and β subunits, which act at separate times of the menstrual cycle 
(Groome et al. 1996). The β subunit exists in two forms, A and B. Subsequently, 
there are two forms of inhibin: inhibin A (α-βA) and inhibin B (α-βB). Inhibin 
B is primarily a product of the developing follicle, whereas inhibin A is de-
rived from the dominant follicle and the corpus luteum (Tong et al. 2003). 
Inhibin has been a strong candidate gene for POF because of its important 
role in regulating ovarian function both as a negative feedback regulator of 
FSH secretion and as a local paracrine factor in the ovary. A decline in inhibin 
levels is associated with a decline in the follicular reserve when approaching 
menopause. This decline of inhibin results in elevated FSH concentrations, in-
creased follicular recruitment, and thus an acceleration in the rate of follicular 
depletion (Richardson et al. 1987, MacNaughton et al. 1992, Chand et al. 2010) 
(Figure 6). Thus, a mutation in the inhibin genes would result in a rise in the 
FSH concentration and follicle loss, leading to POF. Inhibin α is encoded by 
the INHA gene on chromosome 2q33 and it has been implicated in the etiol-
ogy of POF. One mutation of the INHA gene, G769A, has been associated with 
non-syndromic POF with a prevalence of approximately 5%, depending on the 
population studied (Shelling et al. 2000, Shelling 2010, Marozzi et al. 2002, 
Dixit et al. 2004). However, while there are also asymptomatic carriers of the 
mutation, there is heterogeneity in the phenotypes of the INHA G769A muta-
tion carriers (Chand et al. 2010), suggesting that this mutation is more of a 
susceptibility factor for POF (Shelling 2010). Interestingly, Inha knockout mice 
present with raised FSH levels, infertility, and sex cord- stromal tumors at an 
early age, showing that in mice inhibin B functions as a tumor suppressor in the 
gonads (Matzuk et al. 1992).
               
REVIEW OF THE LITERATURE
23
Figure 6. In older women and POF, a decreased number of follicles leads to a re-
duced production of inhibin B and subsequently increased FSH, in comparison to 
young women. Adapted from Shelling 2010.
2.2.5 Symptoms and Diagnosis of POF
POF can present as primary amenorrhea, i.e. absence of menses in a 15-year-old 
girl, or as secondary amenorrhea, i.e. the cessation of menses for 4 months or 
more. The patient may also have menopausal symptoms, such as hot flushes, 
night sweats, fatigue, mood changes, and sexual dysfunction. A prolonged ex-
posure to reduced estrogen levels increases the risk for developing osteoporo-
sis. Secondary amenorrhea with concomitantly raised FSH concentrations is 
suggestive of ovarian insufficiency (Goswami and Conway 2005). 
2.2.6 Prognosis of POF
Treatment of POF comprises dealing with the menopausal symptoms, reducing 
the risk of osteoporosis, and dealing with the loss of fertility (Shelling 2010). 
Ovarian failure usually takes several years to develop, and occasionally ovar-
ian function can intermittently be recovered in the early stages of the disor-
der, which may lead to ovulation and successful pregnancies in up to 5-10% 
of patients with ovarian insufficiency (Nelson et al. 1994, van Kasteren et al. 
1999, Bidet et al. 2008). However, the likelihood for recovery of ovulation is not 
possible to predict. Accordingly, the only reliable fertility treatment is in vitro 
fertilization (IVF) with the use of ovum donation. In most cases of POF, the con-
dition develops over time, such that there is a period of increasing FSH before 
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POF is established. During this time, cryopreservation of oocytes or ovarian 
tissue for later in vitro growth and maturation may be possible (Picton et al. 
2008). While there are few symptoms of an approaching POF, early detection 
and identification of specific molecular defects would also provide a better op-
portunity for an early intervention.
2.3 Testicular Health
2.3.1 Normal HPG Axis during Adult Male Life
The adult testis has two major functions: the production of spermatozoa (fer-
tility) and the secretion of testosterone (virility) (McLachlan et al. 2002a). In 
post-pubertal males, the GnRH pulse generator maintains the gonadotropin 
levels required for normal gonadal function (Isidori et al. 2008). FSH and LH 
stimulate steroid secretion and germ cell production in the testis (Figure 7). 
Male reproductive capacity is usually attained between the ages of 16 and 19 
years. By the end of puberty, plasma testosterone concentration has reached 
adult male levels of 10-35 nmol/l, steady sperm production levels have been 
attained, and plasma concentrations of FSH and LH are in the adult range. The 
testis consists of the seminiferous tubules, comprising 80-85% of the testicular 
mass, surrounded by interstitial tissue containing the Leydig cells as well as 
lymphatic and blood vessels. LH stimulates the Leydig cells to produce testo-
sterone, which partly is aromatized into estradiol. In turn, both testosterone 
and estradiol exert a negative feedback effect on LH and GnRH. Testosterone 
acts through androgen receptors (ARs), which are located on Sertoli cells, 
Leydig cells, and the peritubular myoid cells, but not on germ cells (Bremner et 
al. 1994, Johnston et al. 2001). FSH stimulates Sertoli cells to produce inhibin B, 
which has a negative feedback effect on the pituitary secretion of FSH. 
The Sertoli cells lie on the basement membrane of the seminiferous tubules 
and extend all the way to the lumen. These cells provide nutrients, growth fac-
tors and support to the germ cells, and since each Sertoli cell only can support a 
given number of germ cells, they are the critical determinant of testicular size, 
seminiferous tubule development, and sperm count. Subsequently, in adults, 
inhibin B is a clinically applicable marker of Sertoli cell function, i.e. the go-
nadal reserve (Isidori et al. 2008). 
In contrast to women, who experience a rather complete cessation of ovar-
ian function in menopause, men have continuous spermatogenesis throughout 
their lifespan. During senescence, however, the feedback system of the HPG 
axis is altered, leading to a disorganized GnRH pulsatility and an increase in 
LH and FSH levels due to a diminished testicular responsiveness (Atwood et 
al. 2005, Vadakkadath et al. 2005), ultimately leading to a gradual decrease in 
male sexual function. 
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Figure 7. The HPG axis in males. Adapted from Bellin et al. 2009.
2.3.2 Testicular Failure and Infertility
The etiology of defective sperm production or function can be categorized as 
factors affecting the pre-testicular, testicular, or post-testicular level (Krausz 
2011). Pre-testicular causes of infertility include two principal types of patho-
logical conditions: hypogonadotropic hypogonadism (HH, also called second-
ary hypogonadism, both congenital and acquired) and coital disorders (such 
as erectile dysfunction and retrograde ejaculation). Post-testicular causes com-
prise all obstructive lesions of the seminal tract, infections and inflammations 
of the accessory glands, and autoimmune infertility. Testicular causes lead to 
primary testicular failure, or hypergonadotropic hypogonadism (also called pri-
mary hypogonadism), which accounts for up to 75% of male factor infertility 
(McLachlan and O’Bryan 2010, Krausz 2011). This condition is characterized by 
high serum FSH and LH and low testosterone levels. Adult men with primary 
testicular failure are infertile or subfertile.
REVIEW OF THE LITERATURE
26
2.3.3 Pathophysiology of Primary Testicular Failure
Primary testicular failure may result from a large number of different patholo-
gies, including bilateral cryptorchidism, orchitis, testicular injury, iatrogenic caus-
es, some systemic diseases, and genetic factors (Krausz 2011). Spermatogenesis 
is a complex process by which mature germ cells are produced through strin-
gently controlled cell proliferation, meiosis, and differentiation. More than 
2300 genes are estimated to be involved in this process (Schultz et al. 2003). 
Thus, it is very likely that mutations or polymorphisms in candidate genes in-
volved in different stages of spermatogenesis are responsible for the majority 
of idiopathic forms of primary testicular failure. 
During fetal life, primordial germ cells (PGC) differentiate into gonocytes, 
which give rise to spermatogonia postnatally. The spermatogonia are located 
close to the basement membrane of the seminiferous tubule, and they prolif-
erate through mitosis to give rise to a reserve of undifferentiated stem cells, 
or more seldom, primary spermatocytes. The primary spermatocytes proceed 
via the first meiotic division to become secondary spermatocytes, and fol-
low through a second meiotic division to become haploid round spermatids. 
The round spermatids finally undergo a series of molecular and morphologi-
cal changes to produce mature spermatozoa (Figure 8). Subsequently, mature 
spermatozoa are released into the tubular lumen and advance to the epidi-
dymis for capacitation, the biochemical process by which sperm gains its mobil-
ity and the capability to fertilize an egg (Grootegoed et al. 2000). 
Spermatozoa are produced continuously during the life of adult males. LH and 
FSH control the spermatogenic process by paracrine signaling; in the testis, LH 
receptors are found only in the Leydig cells, and FSH receptors are found only 
in the Sertoli cells. In response to LH, Leydig cells produce testosterone, which 
diffuses into the seminiferous tubules. Both FSH and testosterone are impera-
tive for normal spermatogenesis; FSH is required for qualitative and quantita-
tive normal spermatogenesis, and a high tubular testosterone concentration is 
crucial for germ cell maturation. 
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2.3.4 Genetic Causes for Primary Testicular Failure and Male 
Infertility
2.3.4.1 Syndromic Primary Testicular Failure
There are relatively few established genetic causes of male infertility. The rate 
of chromosomal anomaly among infertile men, however, is high: an 8-to 10-fold 
higher prevalence compared to fertile men (Chandley 1998). Chromosomal ab-
normalities associated with male infertility can be classified as numerical, struc-
tural, or those affecting the Y chromosome. Klinefelter syndrome (KS), 47,XXY, 
is the most prevalent chromosomal defect, accounting for approximately 11% 
of azoospermic cases (Van Assche et al. 1996). The classic phenotype of KS in-
cludes tall stature, gynecomastia, small testes and hypergonadotropic hypogo-
nadism (Klinefelter et al. 1942, Wikström and Dunkel 2011). The phenotype is 
highly variable, and thus it is estimated that most KS men will never receive 
diagnosis (Bojesen et al. 2003). The only constant clinical finding in KS is small 
testes (2-4 ml) (McLachlan and O’Bryan 2010). Histologically, the testes of KS 
men are characterized by Sertoli-cell-only syndrome and hyalinized tubules 
(McLachlan et al. 2007). However, many patients have small foci of sperma-
togenesis that allows the isolation of testicular sperm in 40-69% of nonmosaic 
KS patients (Friedler et al. 2001, Levron et al. 2000, Schiff et al. 2005, Tournaye 
et al. 1996). This permits the use of intracytoplasmic sperm injection (ICSI) and 
enables the possibility of biological offspring for these patients (Palermo et al. 
1998). Interestingly, sperm from most KS men have a normal 23X or Y comple-
ment (McLachlan and O’Bryan 2010).
Bloom syndrome (OMIM 210900) is an autosomal recessive disorder caused by 
mutations in the BLM (Bloom syndrome, RecQ helicase-like) gene on chromo-
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lish a reserve of undifferentiated stem cells. Adapted from Sassone-Corsi 1997.
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some 15q26.1 (Ellis et al. 1995). The corresponding protein is a nuclear cell cycle 
regulator, deficiency of which leads to hypermutability (Ellis and German 1996, 
Auerbach and Verlander 1997). Bloom syndrome is characterized by intrauter-
ine growth restriction (IUGR), sunlight sensitivity leading to telangiectasia ery-
thema, immunologic deficiency, and an increased risk for neoplasia. Males are 
infertile and usually present with azoospermia and small testes (Bloom 1954, 
1966). About 150 patients are known to exist, and the carrier rate is approxi-
mately 1% among Ashkenazi Jews (Passarge 1991, Roa et al. 1999). In contrast, 
female patients with Bloom syndrome report variable hypogonadism but are 
fertile (Hall 2010).
Noonan syndrome (NS; OMIM 163950) is a quite common multiple malforma-
tion syndrome with an estimated incidence of 1 in 500 (Noonan 1994). About 
50% of patients have mutations in the PTPN11 (protein tyrosine phosphatase, 
non-receptor type 11) gene (Tartaglia et al. 2001). NS has a wide phenotypic 
variation but typical features include characteristic facies, short stature and 
congenital heart disease, commonly pulmonary stenosis (Noonan 1994). Male 
patients typically have delayed puberty (Noonan 2006) and undescended tes-
tes (Sharland et al. 1992). Although male transmission of NS is seen, fertility 
is impaired (Allanson 2007). This was previously largely attributed to cryp-
torchidism, well known to be associated with compromised fertility (Werder 
et al. 1976, Cortes et al. 2003). However, recent studies indicate that primary 
testicular failure, with both Sertoli and Leydig cell dysfunction, may underlie 
the impaired fertility seen in NS males (Marcus et al. 2008, Ankarberg-Lindgren 
et al. 2011). Female patients with NS typically have delayed puberty but fertil-
ity does not seen to be impaired (Allanson 2007). 
Prader-Willi syndrome (PWS; OMIM 176270) is a complex multisystem disorder 
characterized by short stature, hyperphagia leading to morbid obesity, muscu-
lar hypotonia, developmental delay, and hypogonadism (Gunay-Aygun et al. 
2001, Cassidy and Driscoll 2009). The hypogonadism has been traditionally re-
garded as hypothalamic, but recent evidence suggests that the hypogonadism 
in fact may be central, peripheral, or combined (Eiholzer et al. 2006, Radicioni 
et al. 2012). PWS results from lack of expression of the paternally inherited 
genes in the PWS critical region on chromosome 15 (Buiting 2010). Genital hy-
poplasia, cryptorchidism, and incomplete pubertal development are common 
among male patients (Crinò et al. 2003). Fertility has never been reported in 
PWS males, whereas females with PWS demonstrate variable hypogonadism 
and pregnancies have been reported (Eldar-Geva et al. 2010).
2.3.4.2 Non-Syndromic Testicular Failure
Chromosome Yq microdeletions are the most prevalent identifiable genetic 
cause of spermatogenic failure, accounting for about 10% in non-obstructive 
azoospermic men and 3-5% in idiopathic severe oligozoospermic men (Krausz 
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and Degl’Innocenti 2006). These deletions yield partial or complete removal 
of one or more of the three AZF (azoospermia factor) regions; AZFa, AZFb 
and AZFc, which encode multiple genes involved in spermatogenesis (Vogt et 
al. 1996). In each AZF region, candidate genes have been identified, but their 
role in spermatogenesis remains largely unknown (Skaletsky et al. 2003). The 
vast majority of these microdeletions arise de novo, denoting that this area is 
especially unstable. 
Androgen receptor (AR) gene mutations give rise to androgen insensitivity syn-
drome (AIS; OMIM 300068), an X-linked disorder leading to end-organ andro-
gen resistance. More than 800 different mutations in the AR gene have been 
reported. AIS affects sexual differentiation with varying severity, depending on 
the type and localization of the mutations, ranging from a female phenotype 
(complete AIS; CAIS) to simple defective spermatogenesis in otherwise normal 
males (partial AIS; PAIS) (Hiort et al. 1996, 2000). In unselected infertile men, 
the prevalence of mutations in the AR gene varies between 0-1.7% (Ferlin et 
al. 2006, Rajender et al. 2007).
During the last few years, new gene mutations have been correlated with spe-
cific morphological defects of the spermatozoa. For example, mutations in the 
aurora kinase C gene (AURKC) cause meiotic arrest and lead to the production 
of large-headed polyploid spermatozoa with multiple flagella (Dieterich et al. 
2007, 2009). In addition, a complete deletion of the DPY19L2 (dpy-19-like 2) 
gene is responsible for most cases of globozoospermia, characterized by the 
production of round spermatozoa without an acrosome (Harbuz et al. 2011). 
Mutations in CATSPER1 (cation channel, sperm associated 1) gene are associ-
ated with recessive male infertility (Avenarius et al. 2009), and mutations in the 
dynein genes that encode proteins of the axonemal dynein cluster are associ-
ated with asthenozoospermia. The collective frequency of these mutations in 
the general population is extremely low, however.
Recently, Bashamboo et al. (2010) showed that mutations in NR5A1, a key fac-
tor in gonadal and adrenal development, underlie spermatogenic failure in 
about 4% of otherwise healthy men. NR5A1 is an important transcriptional 
regulator of genes involved in the hypothalamic-pituitary-steroidogenic axis 
(Morohashi et al. 1992, Luo et al. 1994). It is expressed in both Sertoli and 
Leydig cells during the development of the testis and in Sertoli cells during 
prepuberty and adulthood (Ikeda et al. 1994, Hanley et al. 1999, Morohashi et 
al. 1994). 
NR5A1 mutations are related to many distinct phenotypes, such as 46,XY par-
tial and complete gonadal dysgenesis, penoscrotal hypospadias, micropenis, 
and interestingly, 46,XX primary ovarian insufficiency (Lin and Achermann 
2008, Lourenço et al. 2009). In Leydic cell-specific Nr5a1 knockout mice, the 
testes are hypoplastic and spermatogonia fail to develop into mature sperm 
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(Jeyasuria et al. 2004). In addition, the mice show diminished expression of two 
genes essential for testosterone biosynthesis, Cyp11a and Star. Accordingly, in 
a study of azoospermic men, expression levels of NR5A1 in testes correlated 
positively with serum testosterone concentrations, indicating a direct connec-
tion between these two factors (Kojima et al. 2006). 
2.3.5 Symptoms and Diagnosis of Testicular Failure
Symptoms of testicular failure are determined by the age of onset and ge-
netic factors. In adult males, primary testicular failure is associated with im-
paired spermatogenesis, low testosterone levels and elevated FSH and LH lev-
els. Consequently, symptoms and signs are due to infertility or androgen defi-
ciency. If the androgen deficiency manifests before the completion of puberty, 
incomplete sexual development, eunuchoidal body proportions, and retention 
of a high-pitched voice will follow. Androgen deficiency developing after the 
completion of puberty is associated with infertility, reduced sexual desire and 
function, small or shrinking testes, and reduced muscle mass. In addition, non-
specific symptoms such as decreased energy and depressed mood can occur 
(Bhasin and Basaria 2011). In isolated spermatogenic failure, LH and testoster-
one levels are normal, thus the patient suffers no symptoms of androgen defi-
ciency (Bhasin 2007).  
2.3.6 Prognosis of Testicular Failure
In contrast to secondary hypogonadism, where fertility often can be restored 
by hormonal therapy, in primary hypogonadism, treatment of infertility may be 
restricted to assisted reproductive techniques, such as intracytoplasmic sperm 
injection (ICSI), the use of donor sperm, or adoption (Bhasin and Basaria 2011). 
In young men with androgen deficiency, testosterone treatment is generally 
favorable with regard to sexual function, energy, body composition, and bone 
density (Cunningham and Toma 2011).




Mulibrey nanism (MUL; OMIM 253250) is an autosomal recessive disorder 
belonging to the Finnish disease heritage and is caused by mutations in the 
TRIM37 gene. Perheentupa and colleagues first described the disorder in the 
early 1970s (Perheentupa et al. 1970, 1973). The name is an acronym from 
MUscle, LIver, BRain and EYe, indicating distinct findings in these organs, and 
from nanism, which stands for short stature. Today, 100 patients from Finland 
and about 40 sporadic cases from the rest of the world are known (Thorén 
1973, Cumming et al. 1976, Voorhess et al. 1976, Similä et al. 1980, Finni and 
Herva 1981, Sánchez-Corona et al. 1983, Cotton et al. 1988, Haraldsson et al. 
1993, Lapunzina et al. 1995, Seemanová and Bartsch 1999, Avela et al. 2000, 
Jagiello et al. 2003, Hämäläinen et al. 2004, 2006, Doğanc et al. 2007).  Each 
year, about two new MUL patients are born in Finland, with an incidence of 
approximately 1/40 000 (Lipsanen-Nyman 1986). The majority of the Finnish pa-
tients come from clustered regions in Savo and North Carelia, in line with the 
other diseases of the Finnish disease heritage. Genetically, the Finnish patients 
form a very homogenous group, whereas all patients carry the same founder 
mutation, named Fin-major, the vast majority in a homozygous form.
The first described MUL patients were characterized by hypoplastic facial fea-
tures, a prominent forehead, and a J-shaped sella turcica. In addition, they 
displayed liver enlargement, fibrous dysplasia of long bones, and cutaneous 
naevi flammei. Nearly all patients carried yellowish dots in the ocular fundi 
(Raitta and Perheentupa 1974). Constrictive pericarditis and congestive heart 
failure were characteristic signs already in the first recognized MUL patients 
(Tuuteri et al. 1974). In addition, a high-pitched voice and a small tongue were 
apparent, and dental crowding was commonly seen (Myllärniemi et al. 1978). 
In 1986, a Finnish monography (Lipsanen-Nyman 1986) systematically evalu-
ated the patients known to that date.
Lipsanen-Nyman et al. characterized the Mulibrey heart disease in 2003. They 
concluded that constrictive pericarditis, myocardial hypertrophy and fibro-
sis constitute the main factors of the heart disease and that over half of the 
MUL patients will ultimately develop congestive heart failure (CHF). The heart 
disease is the main prognostic factor of the patients (Lipsanen-Nyman et al. 
2003). 
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Figure 9. Characteristic facial features in a 2-year-old girl with MUL. Note the fron-
tal bossing, high hairline, low nasal bridge and low-set ears. The pictures are pub-
lished with permission from the patient and her parents.
In 2004, the clinical characteristics at time of diagnosis were analyzed in the 
national cohort of 85 Finnish MUL patients (Karlberg et al. 2004). The authors 
concluded that the clinical features of the Finnish MUL patients form a distinct 
entity, although organ manifestations significantly differ from childhood to 
adulthood and between patients. The most consistent attributes were growth 
failure with characteristic craniofacial features (Figure 9). In infancy, the most 
frequent problems were failure to thrive with feeding difficulties and respira-
tory tract infections, including pneumonias. At the time of diagnosis (median 
age 2.1 years), more than 90% of the patients presented with characteristic 
facial features (scaphocephaly, facial triangularity, high and broad forehead, 
and low nasal bridge). Moreover, nearly all patients were gracile and had thin 
extremities (Figure 10). Other common findings included high-pitched voice 
(96%), yellowish dots in the ocular fundi (79%), mild muscular hypotonicity 
(68%), cutaneous naevi flammei (65%), hepatomegaly (45%), and fibrous dys-
plasia of long bones (25%). Psychomotor development was mostly normal or 
slightly delayed, but approximately half of the patients showed mild hypoto-
nicity in infancy (Karlberg et al. 2004).
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Figure 10. A boy with MUL at age 4 months and 7.5 years. Note the gracile body 
with thin extremities. The pictures are published with permission from the patient 
and his parents.
2.4.2 Growth in MUL
MUL children are born small (short and light) for gestational age (SGA) after a 
median gestation length of 39 weeks (32-42 weeks). Most of the pregnancies 
proceed without substantial complications, although poor fetal growth is of-
ten observed. Adjusted to 40 weeks of gestation, the median birth length for 
girls is 44.8 cm (median hSDS -3.0) and birth weight is 2300g (median SDS -3.0). 
For boys, the median birth length is 45.0 cm (median hSDS -2.8) and weight 
2350g (median SDS -2.9) (Karlberg et al. 2004). In contrast to SGA due to other 
reasons (Gibson et al. 2003), MUL children fail to catch up in growth within 
48 months after birth. Instead, they show a continuous deceleration in both 
relative height and weight during infancy and early childhood, followed by a 
spontaneous, but incomplete catch-up growth up to school age. The pubertal 
growth spurt is typically weak or nonexistent. GH therapy improves prepuber-
tal growth, but has only modest impact on adult height (average +5cm). The 
average final adult height is 136 cm  (median hSDS -5.1) in females and 150 cm 
(median hSDS -4.1) in males (Karlberg et al. 2007).     
                   
REVIEW OF THE LITERATURE
34
2.4.3 Metabolic Features of MUL
With increasing age, MUL patients experience a pronounced change in glucose 
metabolism. While children less than 10 years have low fasting glucose and 
insulin levels, over 90% of the adults display insulin resistance (IR). Of these, 
42% have impaired glucose tolerance (IGT) and 50% have type 2 diabetes, 
developing at a median age of 18.3 years and 26.0 years, respectively. The de-
velopment of IR can also be observed in the patients’ body composition; while 
the children are slim, abdominal obesity begins to develop after puberty and 
42% of the adults are overweight (weight for height >20%). In addition, the 
development of IR is accompanied by changes in lipid metabolism, manifest-
ing as increasing levels of total cholesterol, triglycerides, serum leptin, and uric 
acid with age (Karlberg et al. 2005). GH is an insulin antagonist and may induce 
hyperinsulinemia, but intriguingly, patients treated with GH are slimmer and 
have less metabolic problems as young adults (Karlberg et al. 2007). 
Fatty liver is evident in the majority of adults and adolescents, in addition 
to almost half of the reported prepubertal MUL children. Of all MUL adults, 
more than 80% present with hypertension (>95th percentile for age and 
sex). Accordingly, the majority of adults (70%) fulfil the National Cholesterol 
Education Program (NCEP) criteria for metabolic syndrome (Karlberg et al. 
2005). The pathophysiology behind the development of IR in MUL is unclear. 
IUGR itself is associated with an increased risk of IR explained by an unfavo-
rable mother-child environment followed by a rapid early postnatal weight 
gain (Veening et al. 2003, Eriksson et al. 2003). In MUL, however, the postnatal 
weight gain is very modest and the underlying cause of the growth defect is 
genetic. 
2.4.4 Diagnosis of MUL 
The diagnosis of MUL remains challenging. There is an abundance of condi-
tions leading to intrauterine growth restriction (IUGR), including underlying 
genetic disease of the fetus, placental insufficiency or infections. The combina-
tion of prenatal onset growth failure, dysmorphic facial features, poor weight 
gain, and hepatomegaly should evoke suspicion of MUL in early infancy, how-
ever (Karlberg et al. 2004). The median age at diagnosis of the Finnish MUL 
patients is 2.1 years. In 2004, revised diagnostic criteria were proposed for MUL 
(Table 1). Although none of the features are constant findings in the Finnish 
MUL patients, 99% of the patients presented with at least three of the ma-
jor signs, and two of the minor signs (Karlberg et al. 2004). Three unusually 
mild cases of MUL have been diagnosed among the Finnish patients. All three 
are homozygous for the Fin-major mutation, indicating that the phenotype in 
MUL is variable. Since the identification of the causative TRIM37 gene in the 
year 2000, genetic confirmation of the diagnosis has been possible. For Finnish 
families, screening for the Fin-major mutation is often sufficient. For non-Finn-
REVIEW OF THE LITERATURE
35
ish patients, however, sequencing of the whole TRIM37 gene is necessary. In 
affected families, prenatal genetic counselling is plausible. 
2.4.5 Differential Diagnosis
Disorders with prenatal onset growth failure and dysmorphic craniofacial fea-
tures constitute the main components in the clinical differential diagnosis of 
MUL, Silver-Russell syndrome (SRS) representing the most important of them. 
SRS and MUL patients have a very similar growth pattern, with prenatal onset 
growth restriction and lack of postnatal catch-up growth. In addition, SRS pa-
tients also present with facial dysmorphism, constitutional gracility, and feed-
 
Table 1. Diagnostic criteria and their prevalence in MUL 
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1. Growth failure (A or B or C)  
     A) SGA without catch-up growth 95 
     B) height in children 2.5 SD below population  
          mean for age 
94 
     C) height in adults 3.0 SD below population mean 
 
90 
2. Characteristic radiological findings (A or B)  
     A)  slender long bones with thick cortex and narrow  
medullar channels 
93 
     B) J-shaped (low and shallow) sella turcica 
 
89 
3. Characteristic craniofacial features 90 
          Scaphocephaly, triangular face, high and broad  
          forehead, low nasal bridge and telecanthus 
 
 
4. Characteristic ocular findings 79 
          Yellowish dots in retina 
 
 





1. High pitched voice 96 
2. Hepatomegaly 70 
3. Cutaneous naevi flammei 65 
4. Fibrous dysplasia of long bone 25 
 
 
Three major signs + 1 minor sign or 2 major signs + 3 minor signs are 
required for diagnosis. Adapted from Karlberg et al 2004 
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ing difficulties in infancy. These two conditions have several distinctive fea-
tures, however. SRS is characterized by clinodactyly (curving of the fifth digit), 
small face with prominent triangularity, micrognathia (small jaws) with down-
turned mouth corners, and skeletal asymmetry (Price et al. 1999, Hannula et 
al. 2001, Hitchins et al. 2001), features uncommon in MUL. On the other hand, 
hepatomegaly, fibrous dysplasia, heart involvement and yellow dots in the oc-
ular fundi, which are typical in MUL, are not seen in SRS. However, SRS exhibits 
marked genetic and clinical diversity (Hannula et al. 2001, Hitchins et al. 2001, 
Abu-Amero et al. 2008, Bruce et al. 2008). The classical features of SRS that 
clinically overlap with MUL are associated with hypomethylation of the H19 
imprinting control region (ICR) on chromosome 11p15.5 (Bruce et al. 2009). 
Both MUL and SRS should be kept in mind when evaluating an infant with 
growth restriction and facial dysmorphism. 
2.5 TRIM37 Gene
The gene underlying MUL, TRIM37, was identified in the year 2000 by posi-
tional cloning. The project had been initiated already in the early 1990s (Avela 
et al. 1997, 2000). In MUL patients, this strategy identified four different muta-
tions in a cDNA sequence (KIAA0898; 4111bp) encoding for a previously un-
known member of the RING-B-Box-Coiled-Coil (RBCC) protein family (Avela 
et al. 2000). The KIAA0898 gene was located on chromosome 17q22-23 and 
was named MUL, referring to Mulibrey nanism. The gene was subsequently 
renamed TRIM37, however, while the corresponding protein, TRIM37, was in-
cluded in the newly characterized TRIM protein family (Reymond et al. 2001).
To date, 19 different disease-associated mutations have been identified in the 
TRIM37 gene (Avela et al. 2000, Jagiello et al. 2003, Hämäläinen et al. 2004, 
2006, Kallijärvi et al. 2005, Doğanc et al. 2007, and five unpublished muta-
tions). Of the Finnish MUL patients, 95% are homozygous for the Fin-major 
mutation (c.493-2A>G). This mutation results in aberrant splicing resulting in a 
deletion of five nucleotides from the final mRNA transcript. The Fin-minor mu-
tation (c.2212delG) has thus far been detected in only three Finnish patients, 
who are compound heterozygotes for the Fin-major and Fin-minor muta-
tions. Two additional mutations have been identified in three Finnish patients 
(c.227T>C in one patient and c.1166A>G in two siblings), and these mutations 
were observed together with the Fin-major mutation in compound heterozy-
gote forms (Kallijärvi et al. 2005, Hämäläinen et al. unpublished data). So far, 
all identified TRIM37 mutations seem to produce loss-of-function alleles and a 
non-functioning protein. Thus, there is no evidence of a genotype-phenotype 
correlation in MUL.  
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2.6 TRIM37 Protein
TRIM37 is a typical member of the TRIM protein family, with the N-terminal 
TRIM structure comprising the RING domain, a single B-box domain, and a 
coiled-coil region (Figure 11). An internal TRAF (tumor necrosis factor (TNF) re-
ceptor associated factor) domain follows the TRIM domain (Zapata et al. 2001). 
The C-terminal part of TRIM37 has no recognized functional domains and is 
also the least conserved part of the protein (Avela et al 2000). TRAF family pro-
teins are commonly involved in TNF receptor signaling and function as adaptor 
proteins for a diversity of cell surface receptors, involved in regulating apopto-
sis, cell survival, and cellular stress responses (Bradley et al. 2001). 
Northern blot analysis proves that TRIM37 mRNA is widely expressed in adult 
human tissues, with the highest levels in testis and brain (Avela et al. 2000). 
TRIM37 mRNA expression is also broadly detected in many tissues during hu-
man and mouse embryogenesis. Particularly high expression is seen in dorsal 
root and trigeminal ganglia, liver, and epithelia of several organs. 
Like several other RING proteins (Borden 2000), TRIM37 also possesses ubiqui-
tin E3-ligase activity, although the precise biological function of the protein is 
still unknown (Kallijärvi et al. 2005).
   
Figure 11. A schematic structure of the TRIM37 protein. The four Finnish mutations 
are depicted; the Fin-major mutation in the yellow box and the Fin-minor in the 
pink box.
2.6.1 TRIM37 and Peroxisomes
MUL is currently classified as a peroxisomal disorder, due to the fact that TRIM37 
localizes to peroxisomes in immunofluorescence studies (Kallijärvi et al. 2002). 
No known peroxisomal targeting signals have been identified in TRIM37, 
however, which means that the localization may be contingent on interaction 
partners. The coiled coil region of TRIM proteins is sufficient and crucial for 
their correct localization to subcellular compartments (Reymond et al. 2001). 
Accordingly, the Fin-major mutation disrupts the coiled coil region and subse-
quently, mutant TRIM37 loses its peroxisomal localization. On the other hand, 
the coiled coil region remains intact as a result of the Fin-minor mutation and 
the mutant protein targets correctly to the peroxisomes (Kallijärvi et al. 2002). 
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Peroxisomes are cellular organelles with an imperative role in the metabolism 
of lipids and other essential biomolecules (Wanders and Waterham 2006). Until 
recently, peroxisomes were regarded as autonomous organelles, but emerg-
ing evidence show that peroxisomes have functional and physical interactions 
with other cellular organelles, for example with mitochondria. Peroxisomes 
and mitochondria collaborate closely in several metabolic pathways, including 
β-oxidation of fatty acids and the metabolism of reactive oxygen species (ROS) 
(Schrader and Yoon 2007, Thoms et al. 2009). 
Peroxisomal disorders can be divided into two groups, peroxisomal biogenesis 
disorders (PBDs) and single peroxisomal protein defects (Weller et al. 2003). 
PBDs are severe, autosomal recessive disorders caused by mutations in the PEX 
genes. These mutations result in failure to assemble the organelle, and lead 
to defects of multiple peroxisome functions (Thoms et al. 2009). PBD patients 
have a progressive metabolic disease and developmental disorder. The clinical 
picture includes facial dysmorphism, skeletal, liver, and ocular abnormalities, 
and neurological symptoms including muscular hypotonia, failure to thrive, 
seizures, and slow or absent psychomotor development (Weller et al. 2003). 
One of the most severe PBDs is Zellweger syndrome (ZW, OMIM 214100), in 
which patients suffer from a severe neurodevelopmental disorder and, in the 
classical form, seldom survive the first year of life (Steinberg et al. 2006). 
Single peroxisomal protein defects lead to deficiency of a specific peroxiso-
mal function and are either autosomal recessive or X-chromosomal recessive. 
X-linked adrenoleukodystrophy (X-ALD, OMIM 300100), resulting from altera-
tions in the ABCD1 gene, is the most prevalent single protein defect. X-ALD 
results in defective peroxisomal ß-oxidation and subsequent accumulation 
of very long chain fatty acids (VLCFAs) in all tissues, primarily affecting the 
adrenal cortex and the nervous system. The phenotype is highly variable and 
ranges from asymptomatic to severe neurological deterioration in childhood, 
with varying degrees of adrenal insufficiency (Gärtner et al. 1998, Moser et al. 
2007, Thoms et al. 2009). 
MUL is not a typical member of the peroxisomal disease spectrum. Although 
some features are shared, especially with the PBDs, other characteristic findings 
of peroxisomal disorders, such as neurological abnormalities including mental 
retardation, are rarely seen in MUL. Facial dysmorphism, growth restriction, 
retinal changes, muscular hypotonia and hepatomegaly are seen in both con-
ditions, however. In fact, peroxisomal function has previously been evaluated 
in two MUL patients, revealing no biochemical evidence of major peroxisomal 
dysfunction (Schutgens et al. 1994). Nevertheless, MUL is currently regarded as 
a peroxisomal disorder. 
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2.7 TRIM Protein Family
Members of the family of tripartite motif (TRIM)-containing proteins are char-
acterized by a RING finger domain, one or two zinc-binding motifs (named 
B-boxes) and an associated coiled coil region (Reymond et al. 2001). The TRIM 
structure is highly conserved in order and spacing, suggesting a common gen-
eral function to the tripartite motif proteins. The RING domain is consistently 
found in the N-terminus of these proteins, whereas the C-terminus contains 
variable domains. Today, more than 70 TRIM proteins have been identified in 
humans and mice, encoded by approximately 71 genes in man (Hatakeyama 
2011). Many of these genes are clustered together, for example in addition 
to TRIM37, the long arm of chromosome 17 also carries TRIM25, TRIM47, and 
TRIM65. TRIM proteins can further be divided into subfamilies, I to XI, on the 
basis of differences in their domain structure (Short and Cox 2006); TRIM37 
is the sole member of subfamily VIII. TRIM proteins may form homodimers, 
heterodimers, or even trimers, suggesting that TRIM proteins can vary their 
substrate specificity by changing their binding partner (Reymond et al. 2001, 
Herquel et al. 2011).  
TRIM family proteins are involved in an extensive range of biological processes, 
including transcriptional regulation, development, cell growth, apoptosis, and 
tumorigenesis. Accordingly, alterations in TRIM proteins are associated with 
diverse pathological conditions, such as developmental disorders, viral infec-
tions, and cancer (Ozato et al. 2008, Mc Nab et al. 2011, Meroni and Diez-Roux 
2005). 
2.7.1. TRIM Proteins in Cancer
Several TRIM family proteins are involved in carcinogenesis and cancer progres-
sion (Table 2). For example TRIM25, the corresponding gene (TRIM25) of which 
is located in the same cluster as TRIM37 on chromosome 17, has been implicat-
ed in ovarian, breast, and endometrial cancer. The expression of TRIM25 is in-
duced by estrogen, and TRIM25 protein is abundantly expressed in the female 
reproductive organs, as well as in breast and ovarian cancer. TRIM25 mediates 
the ubiquitination and degradation of 14-3-3 sigma, which is a negative cell 
cycle regulator that causes cell cycle arrest (Urano et al. 2002). Loss of Trim25 in 
mouse embryonic fibroblasts causes an accumulation of 14-3-3 sigma, leading 
to reduced cell proliferation. Trim25-/- mice are viable and fertile, but the uteri 
of Trim25-/- female mice are markedly underdeveloped, suggesting that TRIM25 
is imperative for estrogen-mediated cell proliferation in the uterus (Orimo et 
al. 1999, Hatakeyama 2011). 
The RING domain is strongly associated with ubiquitination (Joazeiro and 
Weissman 2000), and today it is recognized, that the majority of TRIM proteins 
function as E3 ubiquitin ligases (Borden 2000, Hatakeyama 2011). For example, 
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the tumor suppressor gene BRCA1 encodes for a RING finger E3 ligase BRCA1. 
Germline mutations in BRCA1 predispose women to early onset breast and 
ovarian cancer (Starita and Parvin 2003, Mani and Gelmann 2005).
2.8 Ubiquitin-Proteasome System 
Ubiquitination is a post-translational modification of proteins in the eukaryotic 
cell essential for maintaining protein homeostasis (Hershko and Ciechanover 
1982, 1992, 1998). In this highly conserved process, a single molecule or mul-
tiple molecules of the 76-amino acid ubiquitin are covalently conjugated to 
target proteins, thus marking them for degradation. This proteolytic pathway 
is pivotal in the elimination of short-lived regulatory proteins, including those 
that participate in cell cycle regulation, cellular signaling, DNA repair, morpho-
 
Table 2. TRIM proteins implicated in cancer 
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Protein Cancer type 
TRIM8 Glioblastoma 
Laryngeal cancer 
TRIM13 B cell chronic lymphocytic leukaemia 
Chronic lymphocytic leukaemia 
TRIM19 Acute promyleocytic leukaemia 
TRIM24 Papillary thyroid cancer 
Myeloproliferative syndrome 
Liver cancer 
Myelodysplastic syndrome-related acute myeloid leukaemia 
Breast cancer 





TRIM28 Gastric cancer 







TRIM31 Gastric cancer 
TRIM32 Head and neck cancer 
TRIM33 Chronic myelomonocytic cancer 
TRIM40 Colon cancer 
TRIM68 Prostate cancer  
Adapted from Hatakeyama 2011 
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genesis, protein quality control and transcriptional regulation (Hatakeyama 
2011). This pathway also eliminates inappropriately folded, unassembled, oxi-
dized, or otherwise damaged proteins that possibly could form toxic aggre-
gates in the cell. 
The process of ubiquitination involves three steps, each catalyzed by specific 
enzymes, namely ubiquitin-activating enzyme (E1), ubiquitin-conjugating en-
zyme (E2), and ubiquitin ligase (E3) (Pickart 2001b) (Figure 12). Usually, the 
ubiquitin process is repeated, resulting in a polyubiquitin chain, linked by dif-
ferent lysine residues of ubiquitin (Pickart 2001b). Substrates marked with 
a Lys48-linked polyubiquitin chain are usually subsequently targeted to the 
26S proteasome for destruction, whereas monoubiquitinated or Lys63-linked 
polyubiquitinated substrates mainly regulate a diversity of cellular functions, 
including endocytosis, transcription, and DNA repair (Weissman 2001, Hicke 
and Dunn 2003, Mukhopadhyay and Riezman 2007). 
 
Figure 12. The ubiquitin-proteasome system. A) Ubiquitin (Ub) is activated by the 
ubiquitin-activating enzyme (E1) using ATP. B) The activated ubiquitin is transferred 
and bound to the ubiquitin-conjugating enzyme (E2). C) The ubiquitin ligase (E3) 
recognizes the specific E2. D) E3 tags the specific target substrate (S) with ubiqui-
tin. E) The ubiquitin process is usually repeated generating a polyubiquitin chain. 
F) Finally the polyubiquitinated substrate is targeted to the 26S proteasome for 
degradation. Modified from Weissman et al. 2011.
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The E3-ligase is thought to be the component of the ubiquitin conjugation 
pathway that is most directly responsible for substrate recognition, whereas 
the E3 proteins function as scaffold proteins mediating the interaction between 
E2 and the substrate (Hershko and Ciechanover 1998, Scheffner et al. 1995). 
The E3 ligases can thus be named the “quality controllers” of the ubiquitin-
proteasome system (UPS). Each E3 ligase recognizes a unique set of substrates, 
together with a single or few E2 ligases (Borden 2000, Pickart 2001a,b). Some 
substrates can also be targeted by more than one E3 ligase (Mani and Gelmann 
2005). It is estimated that the human genome contains approximately 1000 E3 
ligases, but only a few have been characterized and their substrates recognized 
(Schwartz and Ciechanover 2009). There are two major families of E3 ligases: 
the E3s containing a HECT (homologous to E6-AP C terminus domain), and E3s 
containing a RING-finger domain (Weissman 2001). 
2.8.1 Ubiquitin-Proteasome System in Disease
By degrading mutant and structurally abnormal proteins, the UPS plays a crucial 
role in maintaining homeostasis and normal function in eukaryotic cells (Paul 
2008). Abnormalities in the UPS have been implicated in the pathogenesis of 
several inherited and acquired disorders. The pathologies may result from gain 
or loss of function. In gain of function, a substrate meant for degradation is 
stabilized due to inactivation of an enzyme in the UPS pathway, or from a mu-
tation in a targeting motif in the substrate. In loss of function, the substrate is 
removed in an uncontrolled and accelerated way (destabilized). Subsequently, 
impaired function of the UPS has been linked to the pathogenesis of several ge-
netic, autoimmune, and neurodegenerative disorders (Paul 2008). Furthermore, 
there is increasing evidence that the UPS may play a central role in the patho-
genesis of many malignancies. 
Dysfunction of proteosomal degradation can either enhance the effect of on-
coproteins (by stabilization) or reduce the quantity of tumor suppressor pro-
teins (by destabilization) (Mani and Gelmann 2005, Paul 2008). Some of the 
substrates normally degraded by the UPS, like c-Myc, c-Fos and c-Jun, are on-
coproteins, which may induce malignant transformation if not appropriately 
removed from the cell. Mutation or translocation of c-Myc is associated with 
B-cell lymphomas (Leder et al. 1983). c-Fos and c-Jun have both been implicated 
in colorectal cancer (Milde-Langosch 2005). 
Destabilization of tumor suppressor proteins, such as p53, by an over-activated 
UPS, has also been implicated in tumorigenesis (Paul 2008). The p53 gene, lo-
cated on chromosome 17p13.1, is the most prevalent target in human cancers 
(Hainaut and Hollstein 2000, Hollstein et al. 1991). The p53 protein is a tran-
scription factor, which responds to DNA damage and stress by activating cell cy-
cle arrest and apoptosis to avoid accumulation of damaged cells (Levine 1997). 
p53 is regulated by the E3 ubiquitin ligases MDM2 (RING-type E3 ligase) and 
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E6-AP (HECT-type E3 ligase) (Burger and Seth 2004). Normally, MDM2 regulates 
the basal levels of p53 by targeting it for proteosomal degradation (Honda et 
al 1997, Haupt et al 1997). Amplification of the MDM2 gene, found for exam-
ple in sarcomas, lipomas and liposarcomas, results in overexpression of MDM2 
and causes downregulation and subsequent inactivation of p53 (Momand et al 
1998). 
In addition, TRIM proteins, including TRIM13, TRIM19, and TRIM24, are involved 
in p53-regulated pathways, such as apoptosis and response to DNA damage. For 
example, TRIM24 regulates the ubiquitination of p53 and negatively controls 
p53 levels. The TRIM24 gene is overexpressed in breast cancer, and deletion 
of TRIM24 causes p53-dependent apoptosis, indicating that TRIM24 could be a 
potential therapeutic agent in breast cancers that express wild-type p53 (Tsai et 
al. 2010, Chambon et al. 2011, Hatakeyama 2011). 
Indeed, the hierarchical nature of the UPS provides many targets for specific 
intervention and has accordingly arisen as a promising approach to new anti-
cancer therapies (Burger and Seth 2004). Bortezomib is a proteasome inhibitory 
agent that is already used for the treatment of multiple myeloma (Hideshima et 
al. 2001). Moreover, drugs targeting individual E3 ligases are even more promis-
ing, since they should provide higher levels of sensitivity, as they would be more 
likely to prevent binding to specific substrates. Drugs that inhibit oncogenic 
TRIM proteins could also prove useful in the future (Hatakeyama 2011). 
The von Hippel-Lindau protein (pVHL) functions as a ubiquitin E3 ligase, and is 
part of the VHL ubiquitin ligase complex that regulates the proteasomal degra-
dation of hypoxia-inducible factor-1α (HIF-1α) under normal oxygen conditions. 
HIF-1α normally mediates physiologic responses to hypoxia, by activating the 
transcription of genes that promote angiogenesis, like the vascular endothe-
lial growth factor (VEGF). The von Hippel-Lindau tumor suppressor gene (VHL) 
on chromosome 3p25 is mutated in the autosomal dominant cancer syndrome 
von Hippel-Lindau (VHL; OMIM 193300) (Latif et al. 1993). In this syndrome, pa-
tients develop multiple tumors including renal cell carcinoma, hemangioblasto-
mas, and pheochromocytomas, in addition to cystic changes in multiple organs 
(Kaelin 2002, 2007). Loss of pVHL function leads to a constitutive activation of 
HIF-1α, resulting in an increased expression of VEGF, for example, promoting tu-
mor growth and angiogenesis, and thus predisposing patients to hypervascular 
lesions in different organs (Clifford and Maher 2001, Jung et al. 2006). Although 
it is quite a restricted set of tissues that develop tumors in VHL disease, the VHL 
gene is ubiquitously expressed in most tissues (Los et al. 1996, Kaelin 2007). VHL 
mutations are relatively common in sporadic renal cell carcinoma and sporadic 
hemangioblastomas (Kim and Kaelin 2004). Apart from renal carcinomas, so-
matic VHL mutations are rarely seen in other epithelial cancers, however, occa-
sionally, somatic VHL mutations have been described in colorectal cancer (Giles 
et al. 2006).
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3. AIMS OF THE STUDY
Mulibrey nanism (MUL) is a monogenic peroxisomal disorder with diverse or-
gan manifestations caused by mutations in the TRIM37 gene. The aim of this 
thesis was to study the sexual maturation and fertility of a well-characterized 
population of MUL patients, and to characterize the tumors associated with 
this disorder with a special emphasis on the gynecological tumors. A further 
aim was to evaluate the possible role of TRIM37 in the development of spo-
radic gynecological tumors of the thecoma/fibroma type. 
More specifically, the aims were as follows:
1. To evaluate the sexual maturation and fertility of MUL women. 
2. To study the pubertal development, gonadal function, and fertility of MUL 
boys and men.
3. To characterize the tumors associated with MUL using histopathology and 
immunohistochemistry.
4. To study gynecological tumors in MUL and analyze the role of TRIM37 in the 
development of sporadic fibrothecomas.
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4. PATIENTS AND METHODS
The clinical study of MUL patients, on which this study is based, was initiated in 
year 2000. However, the clinical care of the Finnish MUL patients has primarily 
been centralized to the Children’s Hospital since the 1970s, thus generating a 
large amount of retrospective data, concomitantly analyzed in this study.
4.1 Patients (I, II, III, IV)
The complete study cohort included 92 Finnish MUL patients (0.7-77 years of 
age) diagnosed before 2009, 20 of whom were deceased. All patients met the 
diagnostic criteria for MUL (Karlberg et al. 2004). Of the patients, 86 were ho-
mozygous for the Fin-major mutation (c.493-2A>G) of the TRIM37 gene (Avela 
et al. 2000) and three patients were compound heterozygotes; two for the Fin-
major/Fin-minor (c.2212delG) mutations and one for the c.227T>C/Fin-major 
mutation (Kallijärvi et al. 2005). The diagnoses had been confirmed by genetic 
testing in all but three patients. In two of them, DNA was obtained from family 
members, who were carriers of the Fin-major mutation. The phenotype of the 
third patient left no doubt about the diagnosis. 
In study I, 22 postpubertal women, aged 16-69 years, were studied. Of the 
women, 15 were included in a clinical study and the data on seven women 
(five deceased and two with hystero-salpingo-oophorectomy) were studied 
only retrospectively. Of the patients: 21 were born SGA; 20 had a genetically 
confirmed diagnosis; 19 were homozygous for the Fin-major mutation, and; 1 
was compound heterozygote for the Fin-major and Fin-minor mutations. Of 
the women in the clinical study, 9/15 had received GH.
Material/Method Publication 
Patients I, II, III, IV 
Laboratory examinations I, II 
Semen analysis II 
Radiological studies I, III 
Histology II, III, IV 
Immunohistochemistry II, III, IV 
Mutation analysis IV 
LOH-analysis IV 
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The study cohort in study II included 28 male patients aged 8.7 to 50.0 years 
at the end of the study (9 children and 19 adults, median age 28.8 years), who 
had regular follow-up at the Children’s Hospital from years 2000/2001 to 2010. 
Of the males: 25 were born SGA and all diagnoses had been confirmed geneti-
cally; 26 were homozygous for the Fin-major mutation; 1 was compound het-
erozygote for the Fin-major and Fin-minor mutations, and; 1 patient had the 
c.227T>C/Fin-major genotype. One patient died during the follow-up at the 
age of 14.0 years, 11 males had received GH for a median duration of 9.8 years, 
and none had received androgen replacement therapy. 
Study III included the whole study cohort and study IV included the same pa-
tient population as study I.
4.2 Principles of Follow-Up and Clinical Data Collection (I, II, III, IV)
Children were followed up at 6-12 month intervals (II). Visits included physical 
examination with assessment of height, weight, and pubertal stage according 
to the criteria of Tanner (Tanner and Whitehouse 1979). The length and width 
of the testes were measured with a ruler to the nearest mm. Testicular volume 
was calculated applying the formula 0.52 × length × (width)² (Hansen and With 
1952), using the mean value of the two testes for analyses. In study II, repro-
ductive hormone analyses including serum FSH, LH, testosterone, and inhibin 
B were performed once during childhood (age 2-8 years) and prepuberty (9-11 
years), and once a year after the onset of puberty. From the onset of puberty, 
a GnRH stimulation test was carried out every second year or by clinical indi-
cations. Adults were examined at 2-5 year intervals. In study I, serum FSH, LH, 
inhibin B, estradiol, testosterone, and sex hormone-binding globulin (SHBG) 
were measured. The blood sample was taken during the early follicular phase 
from regularly menstruating women, and after a wash-out period of at least 
six weeks in women receiving hormonal substitution. At each visit, in addition 
to the physical examination, sexual function, and in women, menstrual history 
and gynecological symptoms were recorded (I, II).
The hospital records of all patients were retrospectively analyzed and medical 
history, including laboratory and radiological findings, were recorded (I, II, III, 
IV).
4.3 Laboratory Examinations (I, II and Unpublished Data)
Serum concentrations of FSH, LH and SHBG were measured by time-resolved 
immunofluorometric assays (AutoDELFIA™, Wallac, Turku, Finland) (I, II). For 
FSH, the detection limit was 0.05 IU/liter and the inter-assay coefficient of vari-
ation (CV) was ≤5% in the concentration range 2-78 IU/liter. Similarly, the de-
tection limit for LH was 0.05 IU/liter and the inter-assay CV was <4% in the 
concentration range 0.3-42 IU/liter. FSH and LH levels measuring less than 0.1 
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IU/liter were assessed as 0.1 IU/liter. GnRH testing was carried out by giving 
an intravenous bolus of 100μg GnRH (II). FSH levels were measured at 0, 30, 
60, and 90 min, and the LH levels at 0, 20, 30, and 60 min. Estradiol concen-
trations were assessed by a radioimmunoassay with a sensitivity of 24 pmol/
liter (I). Testosterone concentrations were quantified by a radioimmunoassay 
after separation of the steroid fractions on a Lipidex-5000 microcolumn with 
a detection limit of 0.1 nmol/liter (I, II). After the year 2005, testosterone con-
centrations were assayed utilizing a liquid chromatography-tandem mass spec-
trometric (LC-MS/MS) method (II). The detection limit was 0.15 nmol/liter and 
the interassay CV was 4.2-7.6%. Serum inhibin B levels were measured by ELISA 
(Serotec, Oxford, UK), with an assay sensitivity of 15.6 pg/ml, an interassay CV 
of <15% and an intra-assay CV of <5% (I,II). Normal reference ranges were 
attained from the Helsinki University Central Hospital Laboratory except for 
inhibin B in study II, in which reference values were adapted from Andersson 
et al. 1997.
4.4 Semen Analysis (II)
A semen analysis was offered to all male patients over 16 years of age or turn-
ing 16 during follow-up (n=20). Seventeen men provided a semen sample by 
masturbation after a recommended three days of sexual abstinence and sam-
ples were analyzed within 1 h of collection. Basic semen parameters, includ-
ing semen volume, sperm concentration, sperm motility, and sperm morphol-
ogy were evaluated according to the 1999 World Health Organization (WHO) 
guidelines (Table 4). The Sperm Laboratory of Helsinki University Central 
Hospital performed all semen sample analyses apart from one sample analyzed 
in the Tampere University Hospital. 
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Aspermia No ejaculate  
Azoospermia Absence of sperm in ejaculate 
Oligozoospermia < 15 x 106 sperm/ml of semen 
Asthenozoospermia < 32% progressively motile sperm 
Oligoasthenozoospermia Reduced number and motility of 
sperm 




4.5 Radiology (I, III)
Ultrasound (US) of the abdomen was performed regularly as a part of the 
clinical follow-up of all patients (III). In addition, US of the thyroid gland was 
carried out in adults (III). If suspicion of a tumor was evoked, a magnetic reso-
nance imaging (MRI) scan was performed (III). Fifteen postpubertal women 
were subjected to a gynecological US examination which was performed either 
transvaginally or transrectally utilizing a 5 MHz transducer (Hitachi 520) (I). 
4.6 Histology and Immunohistochemistry (II, III, IV)
Tissue specimens were acquired in surgery or from percutaneous core needle 
biopsies or autopsies (n=17). In study II, testicular specimens from eight pa-
tients (aged 2-28) were obtained at orchiectomy (n=2), testicular biopsy (n=1), 
or autopsy (n=5). Control specimens consisted of four testicular biopsies taken 
on clinical grounds from 5-30 year old male patients without MUL. Formalin-
fixed, paraffin-embedded samples were utilized for the histological and im-
munohistochemical studies.
The tissue expression of endothelial cell markers CD34 (DakoCytomation, 
Glostrup, Denmark), CD31 (PECAM-1; Dako), α-smooth muscle actin (α-SMA; 
Dako), perivascular epithelioid cell (PEC) marker HMB-45 (Dako), cellular pro-
liferation marker MIB-1 (KI67; Dako), and the spermatogonia marker MAGE-A 
(kind gift from Dr. Giulio C. Spagnoli, University of Basel, Switzerland) was stud-
ied by immunoperoxidase staining performed in a traditional way on forma-
lin-fixed, paraffin-embedded tissue samples. Microwave treatment in 10mM/l 
citric acid for 10 min was carried out, or Dako Target Retrieval Solution (S1699) 
(DakoCytomation, Glostrup, Denmark) was used, to enhance the antibody pen-
etration. The slides were thereafter incubated with antibody and the stain-
ing was visualized using the NovoLink (Novocastra Laboratories Ltd, Newcastle 
upon Tyne, UK) polymer detection systems. Amplification of the primary anti-
body reaction was accomplished by incubating the sections with biotinylated 
secondary antibody (Vector Elite ABC Kit; Vector Laboratories Inc., Burlingame, 
CA, USA) or TSA Indirect (Pyramide Signal Amplification Kit, Perkin-Elmer LAS 
Inc., NEL700). 
In study II, the ratio of MAGE-A positive tubules indicating spermatogonia in 
each sample was semiquantitatively assessed as a percentage of positive tu-
bules/sample. At least 200 tubules were counted for each sample. Stainings of 
gonocyte markers octamer-binding transcription factor 3/4 (OCT 3/4) (Santa 
Cruz Biotechnology Inc, CA, USA), placental-like alkaline phosphatase (PLAP, 
Dako), and Sertoli and Leydig cell marker inhibin alpha-subunit (Serotec, 
Oxford, UK), were performed in the Labvision immunostainer (Labvision, CA, 





In study IV, the primary antibody used for the MUL fibrothecomas was anti-
inhibin-α (MCA951S; Serotec, Oxford, UK; 1:80). For TRIM37 staining of normal 
ovary samples, an antigen affinity-purified fraction of rabbit antiserum (60μg/
μl) raised against a synthetic peptide (FPDGEQIGPEDLSFNTDENSGR) corre-
sponding to the C terminus of the TRIM37 protein was used. The TRIM37 stain-
ing was carried out using Vectastain Elite kit (Vector Laboratories) according to 
the manufacturer’s protocol. Immunostaining of inhibin-α was carried out in a 
Dako TechMate 500 automated staining machine.
4.7 Analysis of Sporadic Fibrothecomas (IV)
For the TRIM37 mutation analysis of sporadic fibrothecomas, 15 freshly frozen 
samples of these tumors were obtained from the archives of the Department 
of Obstetrics and Gynecology. Messenger RNA was extracted from the speci-
mens using the Oligotex mRNA midi kit (Qiagen, Hilden, Germany). Next, cDNA 
was synthesized using M-MLV reverse transcriptase (Promega, Madison, WI, 
USA) and random hexamers (Promega) according to the manufacturer’s proto-
cols. Seven overlapping fragments covering the whole open-reading frame of 
TRIM37 were subsequently amplified by polymerase chain reaction (PCR) using 
primers and conditions described in detail in Avela et al. 2000. The resulting 
PCR products were assessed on 1% ethidium bromide-stained agarose gels, 
purified (PCR purification kit; Qiagen), and sequenced using the ABI PRISM 
Dye Terminator, the ABI PRISM dRhodamine cycle sequencing Kit (PerkinElmer, 
Foster City, CA, USA) or Big Dye Terminator (Applied Biosystems, Foster City, 
CA, USA) and run on an ABI Prism 310 Genetic Analyzer (Perkin Elmer). Both 
strands were sequenced and the acquired sequence information was edited, 
aligned and compared to the TRIM37 cDNA sequence (GenBank NM 015294.1) 
using Sequencher 3.1 (Genes Codes Corporation). The 15 fibrothecoma speci-
mens were further analyzed by TRIM37 staining as described in chapter 4.6. In 
addition, loss of heterozygosity (LOH) analysis and methylation analysis of the 
fibrothecoma specimens were carried out, as described in detail in the original 
publication IV. 
4.8 Ethics
The Institutional Ethics Review Board at the University of Helsinki approved 
the study, and the National Authority for Medico-Legal Affairs in Finland (TEO) 
approved the use of clinical and autopsy material for research intentions. All 
patients or their parents or guardians provided informed consent. In addition, 




Sexual maturation, fertility, and tumor predisposition were analyzed in the 
national cohort of the Finnish MUL patients by clinical, hormonal, histological, 
and immunohistochemical methods. The results indicate that MUL is a mono-
genic disorder causing human infertility and failure of sexual maturation as 
well as a high risk of both benign and malignant tumors.
5.1 Sexual Maturation and Fertility in MUL Females
5.1.1 Gonadal Function in Prepubertal and Pubertal MUL Girls 
(I, Unpublished Data)
MUL girls overall presented relatively normal genital anatomy, although the 
labia were often edematous. Serum gonadotropins were normal and the on-
set of puberty occurred spontaneously. Breast development was poor and re-
mained incomplete, while none of the girls reached Tanner stage M5. The pu-
bertal growth acceleration commenced with the onset of breast development, 
but was weak and often not possible to discern. Pubic hair generally appeared 
before the onset of breast development and was adequate. Median age at 
menarche was 14.7 years but showed wide individual variation (range 9.8-17.8 
years). Of the girls, 45% never attained regular periods. Five years after me-
narche, only three patients (14%) menstruated regularly.
5.1.2 Gonadal Function and Fertility in Adult MUL Women 
(I, Unpublished Data)
MUL women displayed hypoplastic breasts and pubic hair was fairly normally 
distributed (Figure 13). The labia were often edematous and the uteri were 
small. The first signs of ovarian failure appeared approximately 1.8 years after 
menarche as a menstrual irregularity, ranging from oligomenorrhea to long 
periods of amenorrhea with episodes of menometrorrhagia. Hormone replace-
ment therapy (HRT) or oral contraception (OC) had been initiated for the ma-
jority of women 1-10 years after menarche. The age for menopausal amenor-
rhea could be estimated only for four patients without HRT; it was between 18 
and 38 years. None of the women had been pregnant, but an ovulatory cycle 
had been confirmed in four patients by repeated ultrasound follicle examina-
tion (in three) and/or luteal phase progesterone measurement (in two). Half 
of the adult women in the cohort were living in a settled relationship and the 
majority suffered from involuntary infertility. The women reported satisfactory 
sexual desire. Serum FSH measurements revealed elevated concentrations in 
10/15 (67%) of the women, indicating ovarian failure. LH concentrations were 
elevated in 8/15 (53%) of the women. Estrogen levels were in the low/normal 
range. Inhibin B levels were elevated in three patients, two of which were 
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concomitantly diagnosed with an ovarian tumor, fibrothecoma (Table 5). The 
third patient with elevated inhibin B levels was diagnosed with a fibrothecoma 
three years after the completion of this study. 
Figure 13. A. An 18-year-old MUL woman. B. A 31-year-old MUL woman. Note the 





* Patients 2, 3 and 15 were later diagnosed with fibrothecoma, explaining the markedly 
elevated inhibin B levels and modest FSH levels, ** follicular phase: 1.0-10 IU/I, luteal 
phase: 1.0-8.0 IU/l, *** follicular phase: 2.0-10 IU/l, luteal phase: 1.0-13 IU/l.  
 

























 Normal range         <10 IU/l**    <10 IU/l***   0.11-0.44 nmol/l   19-101 nmol/l   5.0-200 ng/l  0.9-2.8 nmol/l 
        
1 15 19.7 10.8 0.03 23 18         0.5 
2* 16 6.4 30.2 0.08 36 241         0.8 
3* 19 15.9 5.1 0.19 30 213         1.0 
4 20 8.5 2.3 0.05 56 31         1.3 
5 22 7.7 7.8 0.20 115 34         1.6 
6 23 127.0 95.9 0.06 28 24         1.2 
7 24 11.8 13.6 0.42 20 97         1.0 
8 28 27.7 29.4 0.15 36 47         1.1 
9 30 15.3 9.5 0.29 84 33         1.7 
10 31 49.7 26.1 0.09 40 <15.6         3.3 
11 33 9.9 4.8 0.50 57 65         0.5 
12 35 53.2 30.7 0.05 72 17         1.7 
13 35 89.5 62.2 0.19 36 39         0.9 
14 39 21.2 7.4 0.08 79 18         3.9 
15* 48 1.2 7.2 0.03 52 383         1.0 
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Pelvic US revealed hypoplastic ovaries with no follicles in 11/15 (73%) of the 
women. Three patients had small ovaries with only few antral follicles, and 
only one subject (compound heterozygote) had ovaries with normal morphol-
ogy. Six patients had previously undergone surgery for fibrothecomas, and six 
additional tumors were diagnosed by pelvic US during this study. Altogether, 
ovarian fibrothecomas were diagnosed in 12/22 women, thus presenting a risk 
of fibrothecoma of 55%. All except for one patient presented with oligomen-
orrhea or amenorrhea before tumor diagnosis (Figure 14).
Figure 14. Menstrual history and age at tumor diagnosis in the 12 MUL females 
with fibrothecomas. Adapted from The New England Journal of Medicine (I).
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5.2 Sexual Maturation and Fertility in MUL Males
5.2.1 Gonadal Function in Prepubertal and Pubertal MUL Boys (II)
Genital anatomy appeared to be normal in MUL boys, although the testes 
were already somewhat small in childhood (testicular volume 1-2 ml). Two boys 
(2/28, 7.1%) demonstrated surgically corrected unilateral cryptorchidism, and 
one had congenital cryptorchidism with spontaneous descent, before one year 
of age. No one presented with hypospadias or micropenis. In childhood and 
prepuberty, serum levels of FSH, LH, testosterone, and inhibin B were all within 
the normal range.
Similar to MUL girls, the onset of puberty in boys showed wide individual vari-
ation but occurred spontaneously at a median age of 12.6 years (range 11.1-
15.0). The progression of puberty was fairly normal but incomplete. The ma-
jority (72%) of boys never reached Tanner stage P5G5, while testicular volume 
failed to reach adult measures and/or pubertal hair remained at Tanner stage 
4. No patients had signs of gynecomastia. FSH and, to some extent, LH gradu-
ally increased, from the beginning of midpuberty, to hypergonadotropic levels. 
After an initial normal adolescent increase, testosterone concentrations lev-
eled off and subsequently remained within the low-normal range throughout 
puberty. As puberty progressed, inhibin B showed a clear suppression to low 
levels concomitantly with the FSH increase (Figure 15). 
5.2.2 Gonadal Function and Fertility in MUL Men (II)
The median testicular volume in the 20 MUL adults was 8.7 ml (range 3.5-18.3 
ml), while the median testicular volume in healthy Finnish men is 21 ml (range 
15-28) (Jørgensen et al. 2011). After puberty, the size of the testes typically 
decreased with time and they became softer. All adult men showed signs of hy-
pergonadotropic hypogonadism characterized by elevated FSH and sometimes 
also LH levels, low-normal testosterone levels and low inhibin levels (Figure 
15). In males over 26 years of age, FSH was increased in 85%, while LH was el-
evated in 38%. The two men with FSH concentrations in the normal range, did 
however exhibit exaggerated responses to GnRH. Most of the adults (12/19) 
were either married or living in a settled partnership. The majority (10/12, 83%) 
reported satisfactory sexual desire and function, but two men (2/12, 17%) com-
plained of suppressed libido. 
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Figure 15. FSH, LH, inhibin B, and testosterone levels in MUL males, plotted as 
a function of age. Upper and lower limits of normal indicated by dashed lines. 
Adapted from the Journal of Clinical Endocrinology and Metabolism (II). 
Although 20 men were over 16 years-of-age in the cohort, 17 of these provided 
a semen sample. All samples were pathological (Table 6). They showed either 
severe oligoasthenozoospermia (n=13) or azoospermia (n=4). The median ejac-
ulate volume was 2.0 ml (range 0.3-5 ml), being subnormal (<1.5 ml according 
to WHO) in 35% of the patients. Median sperm concentration was 0.007 x 106 
/ml. Only one patient had spermatozoa with rapid progression (WHO class a), 
the rest had significantly reduced sperm motility. Due to the low sperm density, 
morphological analyses could be carried out only in one sample, which showed 
gross teratozoospermia (Table 6). 
No man had a history of spontaneous fertility. Four men had undergone infer-
tility treatment and in one case the treatment (intracytoplasmic sperm injec-
tion, ICSI, with fresh ejaculated sperm) was successful resulting in the delivery 
of a healthy child.
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5.2.3 Histopathology of MUL Testes (II)
The histological structure of the MUL testes was evaluated in four children and 
four adults. The testes of the three younger MUL children (between 2 – 4.9 
years of age) showed large Sertoli-cell-only (SCO) areas with only a paucity of 
seminiferous tubules containing any spermatogonia (Figure 16). In contrast, 
the number of Sertoli and Leydig cells appeared normal. Also the one puber-
tal sample examined, from a patient aged 14 years, showed large SCO areas, 
although more seminiferous tubules contained spermatogonia than the sam-
ples of the young children. In the four adult samples (aged between 24-38 
years), the testes were characterized by prominently thin germinal epithelia. 
Advanced spermatogenesis, as indicated by the presence of spermatids, was, 
however, seen in few tubules (Figure 16). All four adult samples showed Leydig 
cell hyperplasia. One patient displayed a rare sex cord-stromal tumor, theco-
ma. 
Immunohistochemical staining of all 12 testicular samples was performed in 
order to characterize the testicular degeneration process. Gonocyte markers, 
OCT3/4 and PLAP, were not expressed in any of the samples, however sperma-
togonium marker MAGE-A was expressed in all spermatogonia in both MUL 
and control samples. All MUL samples exhibited a patchy MAGE-A appearance 
in agreement with the focal degeneration process. The mean percentage of 
MAGE-A positive seminiferous tubules was 53% in MUL patients and 88% in 
controls. Inhibin-alpha showed strong staining in Sertoli and Leydig cells in 
both MUL and control subjects. In MUL samples, inhibin-alpha staining showed 
marked Leydig cell hyperplasia, almost resembling adenomatous lesions.
                                
RESULTS
 
Table 6. Comparison between median values for semen variables in 17 




Parameter MUL (range) WHO 
Semen volume (ml) 2 (0.3-5) >1.5 
Total sperm number (106 per ejaculate) 0.022 (0-3.6) >39 
Sperm concentration (106 per ml) 0.007 (0-2.4) >15 
Progressive motility (%) 0 (0-10) >32 
Total progressive motility (%) 0 (0-48) >40 
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Figure 16. Typical testicular histology of MUL patients in comparison with normal 
controls. A) Hematoxylin and eosin (HE) staining of an adult MUL testis. Note the 
thin seminiferous tubules. Only a few pachytene spermatocytes (arrows) and sper-
matids (asterisk) can be seen in the magnification in the insert picture. B) MAGE-A 
staining of the same MUL patient. Note three Sertoli cell-only tubules in the lower 
right corner. C) HE staining of normal adult control, note the thick seminiferous 
epithelia. D) MAGE-A staining of the same control. E) HE staining of the testis in 
a MUL child. F) MAGE-A staining of the same MUL child; note the very few sper-
matogonia and the predominance of Sertoli cell-only tubules. G) HE staining of 
a normal control child. H) MAGE-A staining of the same control with abundance 




5.3 Tumor Formation and Organogenesis in MUL (III, IV)
5.3.1 Tumors
MUL patients presented with a high frequency of benign tumors comprising 
mostly cystic and benign adenomatous lesions. Altogether 232 tumorous le-
sions were detected in 76 patients and 17 autopsy samples (Figure 17). The 
most consistent tumorous lesion was found in the liver, where lesions resem-
bling hemangiomas were found in 49% (35/72) of patients by US. The lesions 
were 5-60 mm in size and frequently enlarged with time. In one-third of the 
patients, however, the lesions fluctuated in size during follow-up and tempo-
rarily vanished in five patients. In all 17 deceased patients (between 0.7 and 48 
years of age), the liver was enlarged and congestive at autopsy. In 16 of these 
(94%), multiple macroscopic lesions of 5-70 mm resembling hemangiomas were 
found. Histological examinations of specimens obtained from the 17 autopsies 
and from 20 liver biopsies (patients between 2.4 to 40 years of age) disclosed 
peliosis, i.e. marked sinusoidal dilatation with a disorganized pattern in rela-
tion to central veins and portal tracts. In these lesions, the lobular architecture 
was focally disturbed and the central veins in these areas were dilated and had 
unusually thick walls. Hepatocytes displayed a normal, or slightly enlarged, ap-
pearance with variable amounts of micro- and macrovesicular lipid droplets. 
The portal tracts and biliary tracts appeared normal, but the degree of fibrosis 
increased with age. No lesions showed evidence of malignancy. Fatty liver was 
continually noted in both the liver biopsies (14/20) as well as in the autopsy 
specimens (13/17).
Half (52%) of the patients had renal cortical cysts, 26% had pancreatic cysts, 
20% had thyroid cysts, 15% had cysts in the central nervous system (CNS), and 
11% had cysts in the reproductive organs. Bilateral nodular cortical hyperplasia 
of the adrenal gland was found in 87% of the histological samples analyzed 
(13/15). In the pancreas, hyperplastic islets, as seen in focal endocrine hyper-
plasia, were evident in all samples analyzed (13/13). In addition, 25% of the 
patients (n=22) had fibrous dysplasia of long bones, four had nodular thyroid 
goitre, two presented with renal angiomyolipomas, one had a renal hamar-
toma containing ovarian tissue, one had a pancreatic serous cystadenoma, and 
one infant presented with a small medullar pheochromocytoma. In addition, 
six adrenal cortical adenomas and two thyroid adenomas were discovered. In 
the female patients, the most frequently found tumors were benign ovarian 
fibrothecomas, which were encountered in more than half (12/22) of the post-
pubertal females. 
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Figure 17. Distribution of tumors in MUL.
Malignant tumors were detected in 15% of the patients (15 tumors in 13 pa-
tients), most commonly in the kidneys. Wilms’ tumor was diagnosed in five 
(6%) of the patients at a mean age of 2.5 years, and two subjects carried a 
renal papillary carcinoma. In addition, two patients presented with thyroid 
papillary carcinoma, one with a medullar thyroid carcinoma in combination 
with squamous-cell metaplasia, one with a gastrointestinal carcinoid tumor, 
one with a neuropituitary Langerhans cell histiocytosis, and one with acute 
lymphoblastic leukemia. Two gynecological malignancies were discovered; one 
ovarian carcinoma and one endometrial adenocarcinoma. 
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5.3.2 Organogenesis in MUL
Signs of disturbed organ development were apparent in many internal organs. 
In the adrenal gland, the general morphology was clearly disturbed; cortical 
and medullary structures intermingled and often the adrenal parenchyma pen-
etrated through the capsule into the surrounding renal tissue or fat. In ad-
dition, many histological specimens showed a fetal-type cortical architecture. 
One female patient had a focus of ovarian tissue in her kidney. All histological 
specimens displayed an abnormally folded pancreatic gland with lipid deposits 
within and surrounding the gland. The spleen was congestive in all autop-
sy samples, containing lymphocytes, but lacking lymph follicles in the white 
pulpa. Correspondingly, a serious lymphatic depletion in the lymph nodes was 
evident.
5.3.3 Immunohistochemistry of Tumor Samples (III)
The histological samples of the internal organs often showed strongly dilated 
and folded blood vessels with abnormally thick walls. Especially in the hilar 
region of the lymph nodes, the blood vessels were markedly large and folded. 
Immunohistochemistry revealed strong positive staining for the endothelial 
cell markers CD31 and CD34 as well as for the myocyte marker α-SMA. In con-
trast, staining for proliferation marker MIB-1, p53 and the marker for PEComa, 
HMB-45, were negative. 
The peliotic lesions in the liver also showed strong positive staining of endothe-
lial cell markers, CD31 and especially CD34, as well as of the myocyte marker 
α−SMA (Figure 18).  The staining pattern clearly differed from control livers, 
where the staining of all markers was restricted to portal areas. Mitotic activity 
in the peliotic lesions was scarce and the expression of MIB-1 was also weak. 
The expression of HMB-45 was negative.
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Figure 18. Typical liver pathology in MUL. A) A peliotic lesion with strong sinusoi-
dal dilatation. B) Strong staining of the endothelial marker CD34 in comparison 
with a healthy control (C). Partly adapted from the Journal of Pathology (III).
5.3.4 Ovarian Tumors in MUL (IV)
Ovarian sex cord-stromal tumors were found in 12 of the 22 (55%) women in 
the cohort. Seven of the tumors were diagnosed as thecomas, four as fibromas, 
and one as a cellular fibroma (Table 7) (Figure 19). Mean age at first tumor di-
agnosis was 29 years (range 16-52 years). The size of the tumors varied from 1 
to 15 cm with a mean diameter of 7 cm. Five of the tumors (42%) were multifo-
cal and in half of the cases the tumors were bilateral. The smaller tumors had 
clear margins, whereas the ovarian morphology was usually disturbed in larger 
tumors. Two patients developed recurrent fibrothecomas, 17 and 18 years after 
the primary surgery. Of the 12 fibrothecomas, 9 (75%) showed inhibin-alpha 
positivity in immunohistochemical staining.








Bilateral Multifocal Recurrence 
1 16 Thecoma 14    
2 22 Thecoma 1    
3 22 Thecoma 5 + +  
4 24 Thecoma 8    
5 24 Fibroma+AF 7 + + + 
6 26 Fibroma 8 + +  
7 28 Fibroma 3 +   
8 32 Fibroma+AF 6 + + + 
9 35 Thecoma 5    
10 35 Thecoma 1  +  
11 36 Thecoma 15   + 
12 52 CF 8 +   
RESULTS
Table 7. Fibrothecomas in MUL females

 
* Age at tumor diagnosis. CF, cellular fibroma, AF, adenofibroma. Adapted 
from Modern Pathology (IV) 
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Figure 19. A) MUL-associated thecoma B) MUL-associated fibroma and C) MUL-
associated cellular fibroma. Partly adapted from Modern Pathology (IV).
5.3.5 Sporadic Fibrothecomas (IV) 
In order to analyze the potential role of TRIM37 mutations in the etiology 
of sporadic fibrothecomas, TRIM37 cDNA was sequenced from 15 sporadic tu-
mor specimens utilizing seven overlapping amplicons. No mutations in TRIM37 
were found. In one tumor, a base-pair change from C→T at nucleotide 398 was 
discovered, resulting in a probable non-significant substitution of valine for 
alanine. In the expression analyses 80% of the sporadic fibrothecomas showed 
either completely negative (48%) or weak (32%) staining for TRIM37 protein, 
and only 20% of the sporadic tumors exhibited immunopositivity that was 
comparable to normal thecal cells (Figure 20). To further analyze the possible 
genetic and epigenetic events leading to the reduced expression of TRIM37 in 
sporadic fibrothecomas, LOH and CpG island promoter hypermethylation in 
these tumors were analyzed. Six percent of the sporadic fibrothecomas exam-
ined showed LOH at the TRIM37 locus. Methylation of the TRIM37 promoter 
area was present in 48% of the sporadic fibrothecomas examined, suggesting 
that this could also be one mechanism in the TRIM37 inactivation.
                 
Figure 20. A) Sporadic fibrothecoma highly expressing TRIM37, B) sporadic fibroth-
ecoma with low TRIM37 expression and C) sporadic fibrothecoma completely neg-
ative for TRIM37. Note positive staining of capillary wall cells. Original magnifica-




The sexual maturation, gonadal function and tumor predisposition of a well-
characterized population of MUL children and adults with a defect in a single 
gene TRIM37 were evaluated here. The results show that all MUL adults devel-
op hypogonadism due to a primary gonadal defect and they are either infertile 
or severely subfertile. Furthermore, these patients experience disturbances in 
organogenesis and are at a high risk of developing both benign and malignant 
tumors in various organs. 
6.1 Sexual Maturation and Gonadal Function in MUL 
Women
MUL women experience spontaneous, albeit often late, puberty with incom-
plete breast development, and early irregularity of menstrual periods with 
subsequent ovarian failure and infertility. The clinical spectrum varied from a 
normal or even early menarche with some years of regular periods to a very 
late menarche with apparent direct transition into severe oligomenorrhea fol-
lowed by amenorrhea, indicating the development of POF.  
The clinical spectrum also varies in non-syndromic POF, and there is no men-
strual history that is characteristic for the development of POF (Nelson 2009). 
Most often, the disorder develops after a normal puberty and regular menses, 
but in about 10% of cases, POF may present as primary amenorrhea (Rebar 
and Connolly 1990). Only 3/22 of MUL women menstruated regularly after 5 
years from menarche. Transition to amenorrhea followed menarche, after a 
time span of between a few months to 13 years, in the absence of hormonal 
treatment. The interval could not be assessed more accurately, as menstrual 
disturbances progressed intermittently, hormone assays were not performed 
regularly, and many of the patients received contraceptive pills, cyclic proges-
tin treatment, or HRT to control bleedings. 
In the majority of POF cases, the underlying cause remains unknown. The de-
tection of several causal genetic defects in humans, experimental models, and 
the recurrent familial forms (in about 10-15% of cases), all point towards the 
fact that POF has a strong genetic component (Persani et al. 2010, van Kasteren 
et al. 1999). However, POF is a heterogeneous disease and even within the 
same family, the expressivity can vary. Thus, in addition to monogenic forms, 
POF is probably a multifactorial disorder in many cases, resulting from the con-
tribution of several predisposing alleles (Persani et al. 2010, Shelling 2010). 
Ovarian failure can result from initially deficient follicle number, abnormally 
rapid follicular loss, or resistance to gonadotropins, and the primary defect 
can lie in the oocytes or the surrounding follicle cells. Normally, the follicular 
atresia already commences in fetal life and the age at ovarian failure is deter-
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mined by the size of the oocyte reserve and the rate of its depletion. Whether 
the oocyte reserve in MUL is deficient at the outset, or if the rate of follicular 
atresia is exaggerated, remains to be elucidated.
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein belonging to the 
transforming growth factor-β family (Cate et al. 1986), which in recent years 
has emerged as a novel measure of the ovarian reserve. In females, granulosa 
cells of the primary, pre-antral, and small antral follicles produce AMH. The 
number of small antral follicles is associated with the extent of the primordial 
follicle pool (Kevenaar et al. 2006), and as the number of antral follicles de-
creases with age, serum AMH levels decline, becoming undetectable in meno-
pause (Van Rooij et al. 2004, 2005). Consequently, serum AMH levels are also 
considered to be a marker for ovarian aging (Broekmans et al. 2008, Broer 
et al. 2011). AMH is also a good predictor of ovarian damage in POF, as AMH 
levels are mostly either significantly diminished or undetectable in this condi-
tion (La Marca et al. 2006, Meduri et al. 2007, Kallio et al. 2012). Accordingly, 
in girls with Turner syndrome (TS), serum AMH levels show promising results 
in assessing ovarian reserve and thus potential fertility (Borgström et al. 2009, 
Purushothaman 2010). In future assessment of the ovarian reserve in MUL girls 
and women, determination of AMH levels will prove valuable.
6.2 Fertility in MUL Women
None of the MUL women reported a history of spontaneous pregnancies and 
all women eventually developed POF. In recent years, there has been some 
debate about whether the term “premature ovarian failure” should be substi-
tuted in favor of the terms “premature ovarian insufficiency” or “premature 
ovarian dysfunction”, which reflect the possibly reversible nature of the condi-
tion and have less negative connotations than the word “failure”. However, 
so far no consensus has been reached and in the case of MUL, POF seems like 
an accurate term to use, since ovarian recovery in MUL has never been docu-
mented and is extremely unlikely.
Infertility is an important issue for most women with POF. Treatments with 
clomiphene, gonadotropins, GnRH agonists, and immunosuppressants have 
not been effective in restoring fertility (Bidet et al. 2008), and the only reli-
able treatment option so far is the use of donor eggs and IVF (Shelling 2010). 
Embryo cryopreservation is already an established method for fertility-pres-
ervation. Cryopreservation of ovarian tissue or oocytes is still considered ex-
perimental, but may be readily available in the future (Picton 2008, Rodriguez-
Wallberg and Oktay 2012). Women with POF probably have follicles of lower 
quality, however, meaning that the follicles should be collected well before 
the ovarian failure actually develops, which requires that the women would be 
aware of an impending POF. 
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It is very uncertain how the body and the uterus of a MUL woman would adapt 
to a possible pregnancy. Pregnancy is associated with major hemodynamic 
changes and thromboembolic risks. Thus, the potential impact that a preg-
nancy may have on the heart disease associated with MUL is a significant issue 
to be taken into account. So far, the risks have been considered too large to 
promote assisted reproductive therapies for MUL women. 
POF and polycystic ovarian syndrome (PCOS) represent two important forms 
of female infertility. POF usually results from an early depletion or dysfunction 
of the oocyte population, whereas PCOS is characterized by ovulatory dysfunc-
tion, hyperandrogenism, and polycystic ovaries, with an accumulation of small 
antral follicles (Goodarzi et al. 2011). In a large proportion of infertile females, 
however, the cause still remains a mystery.
6.3 Sexual Maturation and Gonadal Function in MUL 
Males
A reduction in the number of seminiferous tubules containing germ cells was 
already evident in young and prepubertal MUL boys, but Sertoli and Leydig 
cells appeared to be normal. Serum levels of FSH, LH, testosterone, and inhibin 
B were within normal ranges. The onset of puberty, as assessed by the appear-
ance of pubic hair and initial testicular enlargement, was also within normal 
limits for healthy Finnish boys. Similar to MUL girls, however, a trend toward 
late puberty onset was apparent. Given that MUL boys already presented with 
smaller testes before puberty, a testicular volume of 2.0 ml, instead of the stand-
ard limit of 3.0 ml, was accepted here to indicate onset of puberty. FSH, LH, 
testosterone, and inhibin B levels increased adequately until midpuberty, after 
which the testicular growth and virilization proceeded slowly. Concurrently, 
inhibin B levels decreased and testosterone also leveled off, but FSH, and to a 
lesser extent LH, showed a progressive increase to hypergonadotropic levels.
All adult MUL men showed signs of hypergonadotropic hypogonadism. Their 
mean testicular volume was 8.7 ml, and none reached the normal median vol-
ume of 21 ml for healthy Finnish men (Jørgensen et al. 2011). Klinefelter syn-
drome (KS), although more severe, in many ways resembles the hypogonadal 
picture of MUL men. It is characterized by azoospermia with small firm testes 
of less than 4 ml in volume (Wikström and Dunkel 2011). Small and firm tes-
tes indicate that the germinal epithelium was never, or only transiently, es-
tablished. In contrast, if testicular damage develops after spermatogenesis is 
established, the subsequent collapse of seminiferous tubules leaves the testis 
soft and flaccid. In MUL, the soft and shrinking testes indicate that although 
spermatogenesis is established, it is incomplete and evanescent, possibly due to 
an accelerated rate of germ cell apoptosis. 
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The degree of virilization varied and was usually incomplete, but appeared 
to be satisfactory for the patients. Examination of the testicular histology dis-
played varying degrees of degeneration. Sertoli cells appeared roughly nor-
mal, but Leydig cells characteristically formed hyperplastic areas. The histology 
of the MUL testes suggests an impairment of both the spermatogenic and the 
endocrine function. This impairment was confirmed by a reduction in testicu-
lar size during early adulthood, reflecting the progressive decrement of germ 
cells. 
The increasing levels of LH observed after midpuberty plausibly reflect a com-
pensatory feedback mechanism to sustain sufficient Leydig cell function and, 
subsequently, testosterone production. This is in line with the observed Leydig 
cell hyperplasia and quite satisfactory testosterone levels in adult MUL men. 
The testosterone level, below which symptoms of androgen insufficiency oc-
cur, is not known (Bhasin and Basaria 2011), although values below a thresh-
old of 10.4 nmol/liter are associated with an increased likelihood of symptoms 
(Kelleher et al. 2004, Bhasin and Basaria 2011); only two adult MUL men dis-
played testosterone levels below this threshold. Accordingly, the majority of 
adult men in our cohort reported adequate sexual function; however, one third 
of the men had no present or past sexual relationships, which may indicate low 
sexual desire due to androgen deficiency. 
In KS, androgen replacement treatment is offered to the majority of males 
from the peri-pubertal period in order to assure optimal development of sexu-
al characteristics and to avoid sexual dysfunction (Nielsen et al. 1988). In MUL, 
with all its concurrent pathologies, the risk-benefit decision of testosterone 
treatment is more complicated. Testosterone treatment can potentially induce 
dyslipidemia, liver toxicity, and increased cardiovascular events, for example 
(Cunningham and Toma 2010), all of which could possibly worsen the clini-
cal picture of MUL. Following this study, two MUL males were recommended 
testosterone substitution; one with low testosterone levels after unilateral or-
chiectomy, the other complaining about reduced sexual function and fatigue. 
In addition, exogenous testosterone treatment suppresses the HPG axis and 
thus spermatogenesis (McLachlan et al. 2002b, Cunningham and Toma 2011), 
which may also argue against a routine treatment of MUL males with andro-
gens, especially those with a desire for fertility in the near future. 
Whether the defect in the MUL testes is intrinsic to germ cells or is due to 
failure of Sertoli cells to support the germ cells still needs to be elucidated. In 
postpubertal male mice, TRIM37 is expressed in germ cells from type B sper-
matogonia to early round spermatids, while Sertoli cells, Leydig cells, early 
spermatogonia, and elongated spermatids are negative (Kallijärvi et al. 2006). 
This strongly implicates a primary germ cell defect. The expression of gonocyte 
markers, OCT 3/4 and PLAP, was negative in the testicular samples, indicating 
that gonocytes differentiate adequately to spermatogonia in MUL patients. 
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The testicular samples did contain spermatogonia, as evidenced by MAGE-A 
staining, but spermatocytes and especially spermatids were scant. This implies 
that germ cells have difficulty entering meiosis and that germ cell differentia-
tion is, at least in part, arrested at the spermatogonium stage. One feasible ex-
planation could be an accelerated rate of germ cell apoptosis, the reasons for 
which still need to be elucidated. Interestingly, the samples of the autopsied 
children displayed the most severe histology, probably reflecting the severity of 
the disease, whereas all children had died at young age of MUL complications. 
The pathogenic mechanisms underlying the process of testicular degeneration 
in MUL remain unknown, but the mechanisms leading to the loss of germ cells 
evidently start early in life, possibly already during fetal life, and the fertility 
potential is presumably reduced even before puberty. 
6.4 Fertility in MUL Men
All MUL men presented with severe oligoasthenozoospermia or azoospermia. 
The sperm concentrations ranged from 0-2.4 million/ml, whereas the recent 
WHO reference level is over 15 million/ml (World Health Organization 2010). In 
vitro fertilization (IVF) by ICSI, using either ejaculated sperm or testicular sperm 
extraction (TESE), gives hope for biological paternity to MUL men. To date, 
four MUL men have gone through infertility treatment including ICSI, one of 
them also with TESE, but only one successful pregnancy has been conceived 
thus far, using ICSI with fresh ejaculated sperm. TESE also seems like a promis-
ing method for MUL men, since in Klinefelter patients, it has proven successful 
even with no sperm in ejaculates (Schiff et al. 2005, Vernaeve et al. 2004). Thus, 
one important issue to take into consideration is the possibility of cryopreserv-
ing semen samples from MUL boys during early puberty, postulating that the 
testicular degeneration process in MUL is progressive.
The molecular mechanisms leading to spermatogenic damage in cases of ge-
netic infertility are still unknown. Chromosomal aberrations, such as Klinefelter 
syndrome and Y chromosome microdeletions, account for roughly 5% of infer-
tility in males (Ferlin et al. 2007). Only few monogenic mutations causing male 
infertility have been recognized in humans. Recently, Bashamboo et al. showed 
that missense mutations in NR5A1, encoding for a key transcriptional regulator 
of genes involved in the HPG-axis (Luo et al. 1994), account for 4% of unex-
plained spermatogenic failure in otherwise healthy males (Bashamboo et al. 
2010). NR5A1 plays an important role in gonadal development, as it regulates 
SOX9 (Sry-box 9) and AMH during testis determination and differentiation, 
and regulates the expression of many factors involved in steroid hormone bio-
synthesis and cholesterol mobilization, including HMG-CoA synthase (Lin and 
Achermann 2008, Sekido and Lovell-Badge 2008). This finding is highly inter-
esting, since mutations in NR5A1 are also associated with POF (Lourenço et al. 
2009). Thus, both TRIM37 and NR5A1 represent single-gene defects capable of 
inducing both testicular as well as ovarian failure. 
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Based on our results, it seems clear that all MUL patients will ultimately de-
velop some level of gonadal failure, and therefore the question of whether 
gonadal failure should be added to the list of major diagnostic signs in MUL 
is justified. Many gaps remain in our understanding of the etiology of POF 
and testicular failure. Perception of the basic pathophysiologic mechanisms in 
these conditions, which can be aided by the study of monogenic models, such 
as MUL, provides an opportunity for early intervention, and is crucial for the 
development of new therapies for these patients. Consequently, MUL can be 
regarded as a model disease for infertility, and interestingly, MUL is one of few 
syndromic forms of infertility where both females and males are affected.
6.5 SGA and Gonadal Function
Children with impaired fetal growth are well known to be at a higher risk for 
perinatal morbidity and mortality and for a number of chronic diseases later in 
life, such as hypertension, insulin resistance, type 2 diabetes, and cardiovascu-
lar disease (Hales and Barker 1992, 2001, Barker 1995). 
Growth retardation can result in defective organ systems that may function 
suboptimally later in life. Each organ probably has its own critical time win-
dow during gestation in which adequate development can be affected (Barker 
1992). In pregnancies, which are complicated by fetal hypoxemia and growth 
retardation, the fetal kidneys are affected by reduced growth, development 
and functional capacity (Kurjak et al. 1981, Deutinger et al. 1987, De Bruin et 
al. 1998). Interestingly, the developing kidneys and reproductive organs and 
their respective vascular systems are strongly linked in fetal life. As a conse-
quence of this near anatomical relation, it is very likely that during placental 
insufficiency, not only the kidneys, but also at least the ovaries may suffer from 
a reduced blood flow, which could result in an unfavorable environment for 
the developing follicles and thus result in a diminished follicle population at 
birth (De Bruin et al. 1998).
There are conflicting data about the relationship between SGA and gonad-
al function in both women and men. In infant and adolescent girls, prenatal 
growth failure has been associated with a decreased number of primordial 
follicles (de Bruin et al. 1998), elevated serum FSH concentrations, hyperan-
drogenism, reduced ovulation rates, as well as small uterine and ovarian sizes 
(Ibáñez et al. 2000, 2002a,b). These results have not been confirmed by other 
groups, however (Hernandez et al. 2006, Sadrzadeh et al. 2003, Jaquet et al. 
1999, Legro et al. 2010). 
A suboptimal intrauterine environment may trigger adverse effects on boys’ 
gonadal development and increase the risk of cryptorchidism and hypospadias 
in the newborn (Weidner et al. 1999). These conditions can in turn increase 
the risk for poor semen quality and subsequently decrease fertility in adult 
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life (Jensen et al. 2004, Skakkebaek et al. 2001). In our cohort, cryptorchidism 
was evident in 2 boys (7.1%) and no hypospadias were found. The association 
between SGA and reproductive hormones in adolescent males is not as clear; 
one study found decreased testosterone and elevated LH levels in SGA men 
(Cicognani et al. 2002), whereas another study, in which cryptorchid boys were 
excluded, found no such association and concluded that SGA is not associated 
with adolescent male pituitary-testicular function (Jensen et al. 2007)
The impact of SGA on reproductive function also remains unknown. In 2010, 
Meas et al. investigated 579 adults born SGA from the general population and 
compared them to 703 subjects of the same age in terms of time to pregnancy 
(TTP). The results show that fertility was not reduced in subjects born SGA, and 
TTP was comparable in the two groups (Meas et al. 2010). In MUL, the basic 
genetic defect may affect the gonads (germ cells or supporting cells) directly, 
through general growth restraint, or in both of these ways. 
6.6 Tumors in MUL
MUL is demonstrated here to be associated with an increased risk of benign 
and malignant tumors. In addition, signs of disturbed regulation of organ de-
velopment were evident. A total of 232 tumorous lesions were revealed in 70 
of the 92 patients (76%), meaning that some patients were diagnosed with 
more than one tumor, while others were not affected by any tumors at the 
time of examination. The majority of tumors (85%) were benign, including 
cysts, vascular lesions (hepatic peliosis), adrenal adenoma, parathyroid adeno-
ma, thyroid goiter, pancreatic cystadenoma, renal angiomyolipoma, pheochro-
mocytoma, and ovarian fibrothecomas. Of the patients, 15% exhibited malig-
nant tumors, such as Wilms’ tumor, renal papillary carcinoma, thyroid papillary 
and medullar carcinoma, ovarian and endometrial carcinoma, as well as acute 
lymphoblastic leukemia.
Tumorous lesions of the liver, as detected by ultrasound or MRI, were the most 
frequent tumors encountered in the MUL patients, often already present in 
young children. The lesions consisted of large, blood-filled and cyst-like cavi-
ties that interrupted the normal parenchyma (hepatic peliosis) (Tsokos and 
Erbersdobler 2005). Liver peliosis are rare and benign lesions that are often 
associated with an increased pressure in the hepatic circulation due to cardiac 
failure and pericardial constriction, also commonly seen in MUL. In addition, 
hepatic peliosis has been associated with many other medical conditions, in-
cluding infections, alcohol and steroid abuse, diabetes mellitus, immunodefi-
ciency, and wasting illnesses (Tsokos and Erbersdobler 2005), of which diabetes 
and wasting are likewise seen in MUL (Karlberg et al. 2005, 2007). 
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Vascular anomalies were also apparent in other organs than the liver, such as 
the adrenal and thyroid glands, lymph nodes, lungs and brain, which contained 
cystic blood vessels. These lesions showed abundant positive staining for the 
endothelial marker CD34, which is expressed in both progenitor and mature 
endothelial cells (Pusztaszeri et al. 2006). Normally, CD34 staining is negative 
in hepatic sinuosoids, but positive in hepatocellular carcinoma (Haratake and 
Scheuer 1990, Coston et al. 2008), reflecting an increased capillarization of the 
sinusoids (Dhillon et al. 1992). Benign lesions may occasionally show focal CD34 
positivity, but the intense staining seen in MUL, both in the liver and the lymph 
nodes, is clearly aberrant, and suggestive of a significantly disturbed angio-
genesis (de Boer et al. 2000, Pusztaszeri et al. 2006, Hes and Morreau 2009). 
The weak staining for the proliferation marker MIB-1 is in line with the benign 
nature of the vascular lesions. 
Several organs also showed disturbed architecture and ectopic tissues, imply-
ing a defective control of cell migration. For example, some MUL kidneys con-
tained ovarian or adrenal tissues. Ectopic or accessory adrenal tissues are gen-
erally found along the path of descent of the gonads, but extremely rarely in 
the kidneys (Lack et al. 1997). In addition, the structure of the adrenal gland 
was deformed in several MUL patients, displaying fetal-type architecture and 
mixing of cortical and medullary tissues. These findings, together with frequent 
organ anomalies, speak for a disturbed organogenesis in MUL, the molecular 
basis of which remains to be elucidated. 
6.6.1 Ovarian Tumors in MUL
During the follow-up of female MUL patients, it was observed that in addition 
to POF many of the patients developed ovarian tumors. Of the females in our 
study, 55% presented with ovarian fibrothecomas. These tumors are in general 
fairly uncommon, comprising 1-4% of all ovarian tumors (Young and Scully 1984, 
Roth and Czernobilsky 2011). They originate from the ovarian stromal or thecal 
cells and are often hormonally active, which can induce endometrial hyperpla-
sia and even endometrial adenocarcinoma by prolonged secretion of estrogen 
(Roth and Czernobilsky 2011). Fibrothecomas have, to our knowledge, not been 
described previously in any other condition causing POF, suggesting that the 
TRIM37 protein has an important role in the control of theca cell growth.
Fibromas are composed of spindle, round, or oval collagen-producing cells, 
which resemble fibroblasts. In thecomas, the tumor cells contain lipid, resemble 
those of theca interna, and may contain variable amounts of fibroblasts (Roth 
and Czernobilsky 2011). Thecomas may have fibroma-like areas and vice versa, 
and due to this overlap the tumors are often collectively referred to as fibroth-
ecomas. These tumors usually occur in postmenopausal women (mean age 63 




In three of the patients who were later diagnosed with fibrothecoma, inhibin B 
concentrations were considerably elevated. Despite a clear clinical POF diagno-
sis, their FSH levels were normal at the time of the diagnosis, indicating inhibin 
B-mediated suppression of gonadotropins. Inhibin B is a useful serum marker for 
the diagnosis and follow-up of granulosa cell tumors (Geerts et al. 2009). Our 
results suggest that the inhibin B levels are also elevated at least in a proportion 
of patients with ovarian fibrothecomas. 
More than half of the MUL-associated fibrothecomas were multifocal or bilater-
al, and in three cases the tumors recurred after primary ovary sparing surgery. In 
most cases the tumor was clearly defined from the non-neoplastic ovarian tissue. 
These features strongly suggest that the tumors represent true neoplasias and 
not merely hyperplasia of stromal cells or diffuse ovarian fibromatosis, which is 
a rare non-neoplastic disorder of unknown origin (Young and Scully 1984). Most 
MUL-associated fibrothecomas also expressed inhibin-alpha, a typical feature of 
sporadic fibrothecomas. 
In addition to fibrothecomas, 18% (4/22) of the MUL females had epithelial 
gynecological tumors. Two had serous adenofibromas, which are benign tumors 
composed of a fibroma-like stromal component and glandular structures of cili-
ated epithelium resembling the Fallopian tubes. Their molecular background 
and association with malignant epithelial ovarian neoplasias are unknown. One 
patient had a poorly differentiated ovarian adenocarcinoma diagnosed at the 
age of 33, suggesting that females with MUL could be predisposed to ovarian 
carcinoma, as well. Ovariectomy due to fibrothecomas and a shortened life ex-
pectancy due to the MUL heart disease (Lipsanen-Nyman et al. 2003) may pre-
vent this feature from becoming more evident. One patient presented with a 
uterine endometrial adenocarcinoma and a concomitant new thecoma 9 years 
after her other ovary had been removed due to a thecoma. This case could pre-
sumably be explained by thecoma-associated excessive secretion of estrogen, a 
well-established risk factor for endometrial adenocarcinoma. 
In addition to MUL, ovarian sex cord-stromal tumors are also found in several 
other inherited disorders. Gorlin syndrome (basal cell nevus syndrome; OMIM 
109400), is an autosomal dominant disorder caused by mutations in the human 
homologue of Drosophila patched gene (PTCH) at 9q22.3 (Hahn et al. 1996). This 
disorder is characterized by multiple basal cell carcinomas of the skin, medul-
loblastoma, and ovarian fibromas, which are often bilateral and occur at a mean 
age of 30 years. Sotos syndrome (cerebral gigantism; OMIM 117550), caused by 
mutations in the NSD1 gene (nuclear receptor binding SET domain protein 1) 
(Kurotaki et al. 2002), is another pleiotropic congenital syndrome where ovarian 
fibromas have been described (Chen et al. 2002). Patients with Peutz-Jeghers 
syndrome (PJS; OMIM 175200), caused by mutations of the STK11 gene (serine/
threonine kinase 11) at 19p13.3 (Hemminki et al. 1998), are susceptible to sex 
cord-stromal tumors with annular tubules (Young et al. 1982). 
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The molecular pathogenesis of sporadic fibrothecomas is unknown. Trisomy or 
tetrasomy of chromosome 12 is the most common, and often the only, genetic 
aberration detected by cytogenetic studies in these tumors (Fletcher et al. 1991, 
Liang et al. 2001). A less common finding is monosomy of chromosome 22 (Dal 
Cin et al. 1997), and also imbalances in chromosomes 4, 9, 10, and 18 have been 
found in this group of tumors (Micci et al. 2008, Streblow et al. 2007). Allelic 
imbalance (LOH) at 9q22.3 and 19p13.3 suggests the possible involvement of 
PTCH and STK11 genes in the pathogenesis of sporadic fibrothecomas (Tsuji et 
al. 2005, Connolly et al. 2000, Kato et al. 2004), however no mutations of STK11 
have been identified in this group of tumors to date (Connolly et al. 2000, Kato 
et al. 2004). To our knowledge, LOH involving chromosome 17, site of TRIM37, 
has not been previously reported in the thecoma-fibroma group.
6.7 MUL- a Familial Cancer Syndrome?
Classic cancer syndromes, like Von Hippel-Lindau (VHL), typically show a clear 
recognizable spectrum of tumors and generally the tumors also occur at an 
early age. In MUL, the malignant tumors do not chiefly fit into this picture 
(Hes and Morreau 2009). For example, Wilms’ tumors in MUL were diagnosed 
at a median age of 2.5 years, which is the same age as sporadic Wilms’ tumors 
are detected (Scott et al. 2006, 2008). Nonetheless, the incidence of Wilms’ 
tumor in MUL is clearly elevated (6.5%). In addition, tumors in classic cancer 
syndromes are typically bilateral and multifocal, which also do not apply to the 
malignant MUL tumors. The benign tumors in MUL, however, show several fea-
tures typical of classic cancer syndromes, for example the ovarian fibrotheco-
mas appeared at an unusually early age (29 years versus the mean age of 63 de-
scribed in the literature), and the fibrothecomas were also often bilateral and 
multifocal. Renal cysts were also often seen in both kidneys and two patients 
had bilateral adrenocortical adenomas. In addition, some patients presented 
with more than one tumor, another feature typical for cancer syndromes.  
There are several examples of genes responsible for hereditary cancer syn-
dromes that are defective in sporadic tumors with similar morphology and lo-
cation. The germ line harbors one allele with loss-of-function mutation and the 
other allele is inactivated by mutation, allele loss, or epigenetic events like pro-
moter hypermethylation or translational down-regulation. The high frequency 
of fibrothecomas in the female MUL patients prompted investigation here of 
the TRIM37 gene and protein status in sporadic fibrothecomas. 
No TRIM37 mutations were found in the sporadic fibrothecomas by sequencing 
the whole coding region; however, most sporadic fibrothecomas showed re-
duced or absent TRIM37 protein expression in immunohistochemical analyses. 
The TRIM37 transcript was detected in all sporadic fibrothecomas examined, 
but 80% (20/25) of the tumors showed reduced or absent expression of the 
TRIM37 protein indicating alterations at the translational level. Furthermore, 
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LOH analysis and methylation studies also pointed towards a pathogenic as-
sociation between TRIM37 alterations and development of sporadic fibroth-
ecomas.
Interestingly, one male MUL patient developed a testicular thecoma at the age 
of 24 years. Thecomas are extremely rare in the testis, this being, to our knowl-
edge, only the third case reported in the literature (Schenkman et al. 1983, 
Ueda et al. 2010). The second described thecoma in a male was in association 
with Gorlin syndrome, in which women also are predisposed to thecomas and 
fibromas. The occurrence of a thecoma in the MUL males suggests a possible 
pathogenic association between alterations in TRIM37 and thecoma-formation 
also in men.
Our results show that mutations of TRIM37 predispose to both mesenchymal 
and epithelial ovarian tumors and suggest a possible role for TRIM37 in the 
development of sporadic tumors of the thecoma-fibroma group, implying a 
role for TRIM37 in tumorigenesis. Nontheless, whether MUL will obtain a place 
among the established cancer syndromes in the future, remains to be seen. 
6.8 Pathogenic Mechanisms of Tumor Development in MUL
The molecular basis of the tumor development in MUL remains elusive. TRIM 
proteins regulate many important cellular functions, such as insulin signaling, 
cell proliferation, differentiation, angiogenesis, apoptosis, and oncogenesis 
(Meroni and Diez-Roux 2005, Sun 2006, Rome et al. 2004, Hatakeyama 2011). 
Several TRIM proteins are involved in carcinogenesis and cancer progression 
(Hatakeyama 2011), and TRIM37 can be added to this list. Recently, it has been 
recognized that the majority of TRIM proteins function as E3 ubiquitin ligas-
es (Borden 2000, Hatakeyama 2011), including TRIM37 (Kallijärvi et al. 2005). 
In general, cancer may develop from either stabilization of oncoproteins or 
destabilization of tumor suppressor genes. Interestingly, a growing number of 
cancer-associated proteins have been connected to the ubiquitin-proteasome 
pathway. Defective proteasomal degradation can either enhance the effect of 
oncoproteins or reduce the amount of tumor suppressor proteins, and to date, 
many oncogenes and tumor suppressor proteins have been found to be targets 
of ubiquitination (Mani and Gelmann 2005). 
Von Hippel-Lindau syndrome (VHL) is a hereditary cancer syndrome caused by 
mutations in the VHL tumor suppressor gene (Latif et al. 1993), encoding for 
the E3 ligase pVHL, which ubiquitinates HIF-1α during normoxia (Maxwell et 
al. 1999, Paul 2008). Loss of pVHL function leads to constitutive activation of 
HIF-1α, resulting in an increased expression of hypoxia-inducible genes, includ-
ing VEGF (vascular endothelial growth factor), promoting tumor growth and 
angiogenesis (Jung et al. 2006). Accordingly, the tumors associated with VHL 
have a highly vascular phenotype. Most tissues and cell types express pVHL, 
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suggesting that loss of pVHL may also generally be involved in tumor forma-
tion and angiogenesis (Jung et al. 2006).  
MUL and VHL share some interesting histological and radiological features and 
in both conditions patients are predisposed to cystic and vascular lesions, espe-
cially in endocrine tissues. The tumor spectra in VHL and MUL, however, also 
have clear differences; VHL patients commonly develop hemangioblastomas, 
highly vascular benign tumors composed of stromal cells and blood vessels, 
primarily in the retina, cerebellum, and spinal cord (Kaelin 2007), while peliotic 
lesions in the liver are the most frequent tumor type in MUL. In addition, renal 
cell carcinoma is the most common malignant tumor in VHL (Kaelin 2007), in 
contrast to papillary carcinoma or Wilms’ tumor in MUL. However, like in VHL, 
loss of TRIM37 seems to result in an increased angiogenesis and tumor forma-
tion. Whether this is due to an overexpression of VEGF or stimulation of some 
other angiogenic pathway, remains to be elucidated.
TRIM proteins can thus regulate oncogenesis and tumor progression positively 
or negatively by influencing pathways such as cell proliferation, DNA repair, 
and apoptosis. Recent data also indicate that TRIM proteins are involved in epi-
genetic regulation, suggesting that they could also contribute to tumor sup-
pression or development by indirectly regulating gene expression (Hatakeyama 
2011). Further understanding of the UPS and E3 ligases, including TRIM pro-
teins, may thus generate effective targets for novel cancer therapies in the 
future. The exact role of TRIM37 in tumorigenesis will hopefully be clarified in 
future studies. 
In conclusion, the pathogenesis underlying MUL remains elusive. The finding 
that TRIM37 acts as a ubiquitin E3 ligase (Kallijärvi et al. 2005) is important and 
offers an explanation for the pleiotropic features of the disease. The ubiquitin-
proteasome system (UPS) is significant for normal cell function as it regulates 
normal protein turnover (Hershko and Ciechanover 1998). Apart from tumor 
formation (Sun 2006), impaired ubiquitination has also been implicated for ex-
ample in prenatal growth failure (Sarikas et al. 2008), type 2 diabetes (Casas et 
al. 2007), and cardiomyopathy (Zolk et al. 2006), all common features in MUL. 
Recent evidence also suggests an important role for ubiquitination in game-
togenesis and fertilization. The ubiquitin enzymes, including the E3 ligases, 
are important during spermatogenesis (Sutovsky 2003), and in the mammalian 
oocyte, the UPS has been implicated in oocyte meiosis (Verlhac et al. 2010), in-
dicating a role for the UPS in gametogenesis and hence fertility.  Future studies 
will hopefully shed light on the exact role for TRIM37 in the UPS and its impli-
cations in development and disease.
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6.9 Limitations of the Study
Finnish MUL patients genotypically constitute a very homogenous group. 
Although no genotype-phenotype correlation has so far been demonstrated 
in MUL, it is possible that different TRIM37 mutations do not lead to the same 
hypogonadal and tumor predisposing phenotype. As all published TRIM37 mu-
tations to date seem to produce a non-functioning protein, however, it is likely 
that the phenotypes seen in our patients are not only restricted to the Finnish 
genotypes. 
Despite the fact that our MUL cohort is the largest in the world, the number 
of patients is still small and the age variation was large (0.7-77 years). Owing 
to the small number of patients, statistical analyses could not be performed. 
In studies I and II, when assessing the gonadal function in MUL, age- and sex 
matched controls would have been valuable. In addition, a larger sample size 
of testicular controls would have been valuable in study II, but testicular biop-
sies from healthy controls are very scarce as testicular biopsies are only taken 
on clinical grounds.
6.10 Future Prospects
Further elucidation of the development and timing of the gonadal failure in 
MUL will hopefully shed light on molecular pathways important for sexual 
maturation and fertility. As assisted reproductive technologies continue to de-
velop, biological paternity will probably be possible for more MUL men, but 
the question of biological maternity in MUL still must be considered with much 
caution. The possibility of adoption should also be kept in mind for this patient 
group. 
In patients with MUL, genetic defects in the TRIM37 protein are associated 
with growth restriction, cardiopathy, early onset metabolic syndrome, hy-
pogonadism, infertility, defective organogenesis and tumor formation. In the 
future, expanding the clinical studies to mouse models, and generation and 
characterization of induced pluripotent stem cells (iPS) from MUL patients, will 
offer a unique opportunity to study central cellular functions associated with 





In this study, a well-characterized study population of Mulibrey nanism (MUL) pa-
tients with mutations in the TRIM37 gene were assessed for sexual maturation, 
gonadal function, and tumor predisposition.
The main conclusions of this study are:
1. Female and male hypogonadism, associated with a substantial risk for infertility, 
is a central clinical characteristic of MUL. Gonadal failure should be added to the 
list of major diagnostic signs in MUL. 
2. Female patients with MUL demonstrate incomplete breast development, hypo-
plastic ovaries, a small uterus, and early irregularity of menstrual periods. All MUL 
females eventually develop premature ovarian failure (POF) and no female subject 
has become pregnant. 
3. Male patients with MUL develop a unique disorder of testicular function char-
acterized by small testes, elevated FSH and LH levels, and low inhibin B. No spon-
taneous pregnancies have been conceived among the MUL men; however, IVF by 
intracytoplasmic sperm injection (ICSI) gives hope for biological paternity in MUL, 
and to date, one MUL man has successfully undergone this treatment, resulting in 
the delivery of a healthy child. 
4. TRIM37 represents a new gene associated with POF and testicular failure and 
mutations in TRIM37 can be added to the list of single-gene defects causing hu-
man infertility.
5. MUL patients show a high frequency of both benign and malignant tumors in 
several organs. They are especially prone to benign vascular lesions of the liver, 
hepatic peliosis, and adenomatous lesions. Organogenesis is also commonly dis-
turbed. 
6. Female MUL patients have a high risk of developing benign ovarian stromal tu-
mors, fibrothecomas, and should thus undergo regular gynecological evaluations. 
More precise knowledge of the function of the TRIM37 gene will likely increase 
our understanding of the cellular functions regulating gametogenesis, gonadal 
function, proliferation, migration, and angiogenesis. MUL can thus be regarded 
as a model disease for infertility and tumor formation. Consequently, the study 
of rare monogenic disorders is not merely a treasure trove for elucidating gene 
function and for defining normal and pathological metabolic pathways, but it can 
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